{"id":4823,"date":"2025-08-16T13:01:41","date_gmt":"2025-08-16T10:01:41","guid":{"rendered":"https:\/\/mikrobiologikolamia.gr\/staging\/?p=4823"},"modified":"2025-11-16T12:29:14","modified_gmt":"2025-11-16T10:29:14","slug":"pollaplo-myeloma","status":"publish","type":"post","link":"https:\/\/mikrobiologikolamia.gr\/staging\/pollaplo-myeloma\/","title":{"rendered":"\u03a0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u039c\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1 \u2013 \u03a3\u03c5\u03bc\u03c0\u03c4\u03ce\u03bc\u03b1\u03c4\u03b1, \u0394\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7, \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 &#038; \u039d\u03b5\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u0395\u03be\u03b5\u03bb\u03af\u03be\u03b5\u03b9\u03c2"},"content":{"rendered":"<p><!-- ========================= \u03a0\u039f\u039b\u039b\u0391\u03a0\u039b\u039f \u039c\u03a5\u0395\u039b\u03a9\u039c\u0391 \u2013 \u039f\u0394\u0397\u0393\u039f\u03a3 10.000+ \u039b\u0395\u039e\u0395\u03a9\u039d (\u039c\u0395\u03a1\u039f\u03a3 \u0391) Mobile-friendly HTML \u03b3\u03b9\u03b1 Classic Editor ========================= --><\/p>\n<style>\n  \/* ----- Global: mobile-friendly wrappers ----- *\/<br \/>  .toc{border:1px solid #e5e7eb;border-radius:12px;padding:16px;background:#fafafa}<br \/>  .toc a{display:block;padding:6px 0;text-decoration:none;color:#0f766e}<br \/>  .toc a:hover{text-decoration:underline}<br \/>  .label{display:inline-block;font-size:12px;padding:2px 8px;border-radius:999px;background:#eef2ff;color:#3730a3;margin-left:6px}<br \/>  .infobox{border-left:6px solid #f59e0b;background:#fff7ed;padding:14px 14px 14px 12px;border-radius:10px;margin:18px 0}<br \/>  .infobox.success{border-left-color:#10b981;background:#ecfdf5}<br \/>  .infobox.neutral{border-left-color:#9ca3af;background:#f9fafb}<br \/>  .infobox h4{margin:6px 0 8px 0}<br \/>  .table-scroll{overflow-x:auto;-webkit-overflow-scrolling:touch;border:1px solid #e5e7eb;border-radius:12px;margin:14px 0}<br \/>  .table-scroll table{border-collapse:collapse;width:100%;min-width:640px}<br \/>  .table-scroll th,.table-scroll td{padding:10px;border-bottom:1px solid #e5e7eb;text-align:left;vertical-align:top}<br \/>  .tagcaps{display:flex;flex-wrap:wrap;gap:8px;margin:8px 0 0}<br \/>  .tagcaps span{background:#eef2ff;color:#111827;border:1px solid #c7d2fe;padding:4px 10px;border-radius:999px;font-weight:600;font-size:11px;letter-spacing:.04em}<br \/>  .small{font-size:12px;color:#6b7280}<br \/>  .kb{background:#f1f5f9;border-radius:8px;border:1px dashed #cbd5e1;padding:10px;margin:12px 0}<br \/>  .lead{font-size:18px;line-height:1.7}<br \/>  .anchor{scroll-margin-top:80px}<br \/><\/style>\n<p><!-- ===== SEO\/Intro (\u03c0\u03c1\u03bf\u03b1\u03b9\u03c1\u03b5\u03c4\u03b9\u03ba\u03cc meta text \u03b3\u03b9\u03b1 Rank Math) ===== --><\/p>\n<div class=\"infobox neutral\"><\/div>\n<h2 id=\"toc\" class=\"anchor\">\ud83e\udded \u03a0\u03af\u03bd\u03b1\u03ba\u03b1\u03c2 \u03a0\u03b5\u03c1\u03b9\u03b5\u03c7\u03bf\u03bc\u03ad\u03bd\u03c9\u03bd (TOC)<\/h2>\n<div class=\"toc\">\n<div id=\"toc-container\" style=\"border: 1px solid #ccc; padding: 15px; border-radius: 8px; background: #f9f9f9;\">\n<div class=\"toc\">\n<p><strong>\ud83d\udcd1 \u03a0\u03b5\u03c1\u03b9\u03b5\u03c7\u03cc\u03bc\u03b5\u03bd\u03b1<\/strong><\/p>\n<ol>\n<li><a href=\"#sec-1\">1. \u03a4\u03b9 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03bf \u03a0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u039c\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1; \u039f\u03c1\u03b9\u03c3\u03bc\u03cc\u03c2 \u2013 \u0395\u03c0\u03b9\u03b4\u03b7\u03bc\u03b9\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u2013 \u03a6\u03c5\u03c3\u03b9\u03ba\u03ae \u03b9\u03c3\u03c4\u03bf\u03c1\u03af\u03b1<\/a><\/li>\n<li><a href=\"#sec-2\">2. \u03a0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03b9\u03ba\u03ac \u03bd\u03bf\u03c3\u03ae\u03bc\u03b1\u03c4\u03b1: MGUS vs SMM vs MM<\/a><\/li>\n<li><a href=\"#sec-3\">3. \u039a\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 \u0394\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2 (IMWG): SLiM\u2013CRAB<\/a><\/li>\n<li><a href=\"#sec-4\">4. \u0394\u03b9\u03b1\u03b3\u03bd\u03c9\u03c3\u03c4\u03b9\u03ba\u03cc\u03c2 \u0388\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2: \u0395\u03c1\u03b3\u03b1\u03c3\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ac, \u0391\u03c0\u03b5\u03b9\u03ba\u03cc\u03bd\u03b9\u03c3\u03b7, MRD<\/a><\/li>\n<li><a href=\"#sec-5\">5. \u03a3\u03c4\u03b1\u03b4\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 &amp; \u039a\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2: ISS, R-ISS, R2-ISS<\/a><\/li>\n<li><a href=\"#sec-6\">6. \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u0395\u03b9\u03ba\u03cc\u03bd\u03b1 &amp; \u0395\u03c0\u03b9\u03c0\u03bb\u03bf\u03ba\u03ad\u03c2<\/a><\/li>\n<li><a href=\"#sec-7\">7. \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03a0\u03c1\u03ce\u03c4\u03b7\u03c2 \u0393\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2 (NDMM)<\/a><\/li>\n<li><a href=\"#sec-8\">8. \u0391\u03c5\u03c4\u03cc\u03bb\u03bf\u03b3\u03b7 \u039c\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7 (ASCT)<\/a><\/li>\n<li><a href=\"#sec-9\">9. \u03a3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7 (Maintenance)<\/a><\/li>\n<li><a href=\"#sec-10\">10. \u03a5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03ae\/\u0391\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u039d\u03cc\u03c3\u03bf\u03c2 (RRMM)<\/a><\/li>\n<li><a href=\"#sec-11\">11. \u039d\u03b5\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b5\u03c2: CAR-T &amp; \u0394\u03b9\u03b5\u03b9\u03b4\u03b9\u03ba\u03ac \u0391\u03bd\u03c4\u03b9\u03c3\u03ce\u03bc\u03b1\u03c4\u03b1<\/a><\/li>\n<li><a href=\"#sec-12\">12. \u03a5\u03c0\u03bf\u03c3\u03c4\u03b7\u03c1\u03b9\u03ba\u03c4\u03b9\u03ba\u03ae \u03a6\u03c1\u03bf\u03bd\u03c4\u03af\u03b4\u03b1 &amp; \u03a0\u03c1\u03cc\u03bb\u03b7\u03c8\u03b7 \u0395\u03c0\u03b9\u03c0\u03bb\u03bf\u03ba\u03ce\u03bd<\/a><\/li>\n<li><a href=\"#sec-13\">13. Frailty &amp; \u0395\u03be\u03b1\u03c4\u03bf\u03bc\u03af\u03ba\u03b5\u03c5\u03c3\u03b7 \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<\/a><\/li>\n<li><a href=\"#sec-14\">14. \u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7, \u0391\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7 &amp; MRD<\/a><\/li>\n<li><a href=\"#sec-15\">15. \u03a0\u03c1\u03cc\u03b3\u03bd\u03c9\u03c3\u03b7 &amp; \u03a0\u03b1\u03c1\u03ac\u03b3\u03bf\u03bd\u03c4\u03b5\u03c2 \u039a\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5<\/a><\/li>\n<li><a href=\"#sec-16\">16. \u0395\u03b9\u03b4\u03b9\u03ba\u03ad\u03c2 \u039a\u03b1\u03c4\u03b1\u03c3\u03c4\u03ac\u03c3\u03b5\u03b9\u03c2 (\u039d\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1, \u03b5\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7, \u03b1\u03bc\u03c5\u03bb\u03bf\u03b5\u03af\u03b4\u03c9\u03c3\u03b7, \u03c0\u03bb\u03b1\u03c3\u03bc\u03bf\u03ba\u03cd\u03c4\u03c9\u03bc\u03b1)<\/a><\/li>\n<li><a href=\"#sec-17\">17. \u0396\u03c9\u03ae \u03bc\u03b5 \u039c\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1: \u03a0\u03bf\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1 \u0396\u03c9\u03ae\u03c2, \u0394\u03b9\u03b1\u03c4\u03c1\u03bf\u03c6\u03ae &amp; \u0386\u03c3\u03ba\u03b7\u03c3\u03b7<\/a><\/li>\n<li><a href=\"#sec-18\">18. \u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2 (FAQ)<\/a><\/li>\n<li><a href=\"#sec-19\">19. \u0392\u03b9\u03b2\u03bb\u03b9\u03bf\u03b3\u03c1\u03b1\u03c6\u03af\u03b1 &amp; \u03a0\u03cc\u03c1\u03bf\u03b9<\/a><\/li>\n<\/ol>\n<\/div>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<p><!-- ========================= SECTION 1 ========================= --><\/p>\n<h2 id=\"sec-1\" class=\"anchor\">1) \u03a4\u03b9 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03bf \u03a0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u039c\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1; \u039f\u03c1\u03b9\u03c3\u03bc\u03cc\u03c2 \u2013 \u0395\u03c0\u03b9\u03b4\u03b7\u03bc\u03b9\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u2013 \u03a6\u03c5\u03c3\u03b9\u03ba\u03ae \u03b9\u03c3\u03c4\u03bf\u03c1\u03af\u03b1<\/h2>\n<p class=\"lead\">\u03a4\u03bf <strong>\u03a0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u039c\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1 (Multiple Myeloma, MM)<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 \u03ba\u03b1\u03ba\u03bf\u03ae\u03b8\u03b7\u03c2 \u03bd\u03b5\u03bf\u03c0\u03bb\u03b1\u03c3\u03af\u03b1 \u03c4\u03c9\u03bd \u03c0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd \u03c4\u03bf\u03c5 \u03bc\u03c5\u03b5\u03bb\u03bf\u03cd \u03c4\u03c9\u03bd \u03bf\u03c3\u03c4\u03ce\u03bd. \u03a7\u03b1\u03c1\u03b1\u03ba\u03c4\u03b7\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03cc \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03b1\u03c3\u03b9\u03b1\u03c3\u03bc\u03cc \u03c0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd \u03c0\u03bf\u03c5 \u03c0\u03b1\u03c1\u03ac\u03b3\u03bf\u03c5\u03bd \u03bc\u03bf\u03bd\u03bf\u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03ae \u03b1\u03bd\u03bf\u03c3\u03bf\u03c3\u03c6\u03b1\u03b9\u03c1\u03af\u03bd\u03b7 (M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7) \u03ae\/\u03ba\u03b1\u03b9 \u03b5\u03bb\u03b5\u03cd\u03b8\u03b5\u03c1\u03b5\u03c2 \u03b5\u03bb\u03b1\u03c6\u03c1\u03ad\u03c2 \u03b1\u03bb\u03c5\u03c3\u03af\u03b4\u03b5\u03c2 (FLC), \u03bc\u03b5 \u03b1\u03c0\u03bf\u03c4\u03ad\u03bb\u03b5\u03c3\u03bc\u03b1 <em>end-organ damage<\/em> (\u03bf\u03c3\u03c4\u03ac, \u03bd\u03b5\u03c6\u03c1\u03ac, \u03b1\u03af\u03bc\u03b1, \u03b1\u03c3\u03b2\u03ad\u03c3\u03c4\u03b9\u03bf).<\/p>\n<div class=\"infobox success\">\n<h4>Key points<\/h4>\n<ul>\n<li>\u03a3\u03c5\u03bd\u03ae\u03b8\u03c9\u03c2 \u03c0\u03c1\u03bf\u03b7\u03b3\u03b5\u03af\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03b1\u03c3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c6\u03ac\u03c3\u03b5\u03b9\u03c2 (<em>MGUS<\/em> \u2192 <em>SMM<\/em> \u2192 <em>MM<\/em>).<\/li>\n<li>\u03a4\u03c5\u03c0\u03b9\u03ba\u03ad\u03c2 \u03b5\u03ba\u03b4\u03b7\u03bb\u03ce\u03c3\u03b5\u03b9\u03c2: \u03bf\u03c3\u03c4\u03b9\u03ba\u03cc\u03c2 \u03c0\u03cc\u03bd\u03bf\u03c2\/\u03bb\u03cd\u03c3\u03b5\u03b9\u03c2, \u03c5\u03c0\u03b5\u03c1\u03b1\u03c3\u03b2\u03b5\u03c3\u03c4\u03b9\u03b1\u03b9\u03bc\u03af\u03b1, \u03b1\u03bd\u03b1\u03b9\u03bc\u03af\u03b1, \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1.<\/li>\n<li>\u0397 \u03ad\u03b3\u03ba\u03b1\u03b9\u03c1\u03b7 \u03b4\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7 \u03b2\u03b1\u03c3\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03c3\u03c4\u03b7\u03bd IMWG (SLiM-CRAB) \u03ba\u03b1\u03b9 \u03b7 <em>\u03c3\u03cd\u03b3\u03c7\u03c1\u03bf\u03bd\u03b7 \u03b1\u03c0\u03b5\u03b9\u03ba\u03cc\u03bd\u03b9\u03c3\u03b7<\/em> \u03b5\u03af\u03bd\u03b1\u03b9 \u03ba\u03c1\u03af\u03c3\u03b9\u03bc\u03b7.<\/li>\n<\/ul>\n<\/div>\n<p>\u0397 \u03b5\u03c0\u03af\u03c0\u03c4\u03c9\u03c3\u03b7 \u03b1\u03c5\u03be\u03ac\u03bd\u03b5\u03b9 \u03bc\u03b5 \u03c4\u03b7\u03bd \u03b7\u03bb\u03b9\u03ba\u03af\u03b1 (\u03bc\u03ad\u03c3\u03b7 \u03b4\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7 \u03b3\u03cd\u03c1\u03c9 \u03c3\u03c4\u03b1 65\u201370 \u03ad\u03c4\u03b7). \u03a5\u03c0\u03ac\u03c1\u03c7\u03bf\u03c5\u03bd \u03c6\u03c5\u03bb\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2\/\u03b3\u03b5\u03bd\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b2\u03b1\u03bb\u03bb\u03bf\u03bd\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b5\u03c0\u03b9\u03c1\u03c1\u03bf\u03ad\u03c2, \u03b5\u03bd\u03ce \u03cc\u03bb\u03bf\u03b9 \u03c3\u03c7\u03b5\u03b4\u03cc\u03bd \u03bf\u03b9 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03c0\u03b5\u03c1\u03bd\u03bf\u03cd\u03bd \u03b1\u03c0\u03cc \u03c0\u03c1\u03bf\u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u03bc\u03bf\u03bd\u03bf\u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03ae \u03c6\u03ac\u03c3\u03b7. \u0397 \u03c6\u03c5\u03c3\u03b9\u03ba\u03ae \u03b9\u03c3\u03c4\u03bf\u03c1\u03af\u03b1 \u03ad\u03c7\u03b5\u03b9 \u03bc\u03b5\u03c4\u03b1\u03b2\u03bb\u03b7\u03b8\u03b5\u03af \u03b4\u03c1\u03b1\u03bc\u03b1\u03c4\u03b9\u03ba\u03ac \u03bc\u03b5 \u03c4\u03b7\u03bd \u03ad\u03bb\u03b5\u03c5\u03c3\u03b7 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03c9\u03bd \u03c0\u03c1\u03c9\u03c4\u03b5\u03b1\u03c3\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2, \u03b1\u03bd\u03bf\u03c3\u03bf\u03c4\u03c1\u03bf\u03c0\u03bf\u03c0\u03bf\u03b9\u03b7\u03c4\u03b9\u03ba\u03ce\u03bd, \u03b1\u03bd\u03c4\u03b9-CD38 \u03b1\u03bd\u03c4\u03b9\u03c3\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd, \u03ba\u03b1\u03b8\u03ce\u03c2 \u03ba\u03b1\u03b9 <em>CAR-T<\/em> \u03ba\u03b1\u03b9 <em>\u03b4\u03b9\u03b5\u03b9\u03b4\u03b9\u03ba\u03ce\u03bd \u03b1\u03bd\u03c4\u03b9\u03c3\u03c9\u03bc\u03ac\u03c4\u03c9\u03bd<\/em>.<\/p>\n<p><!-- ========================= SECTION 2 ========================= --><\/p>\n<h2 id=\"sec-2\" class=\"anchor\">2) \u03a0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03b9\u03ba\u03ac \u03bd\u03bf\u03c3\u03ae\u03bc\u03b1\u03c4\u03b1: MGUS vs SMM vs MM<\/h2>\n<div class=\"table-scroll\">\n<table>\n<thead>\n<tr>\n<th>\u039f\u03bd\u03c4\u03cc\u03c4\u03b7\u03c4\u03b1<\/th>\n<th>\u039f\u03c1\u03b9\u03c3\u03bc\u03cc\u03c2\/\u039a\u03cd\u03c1\u03b9\u03b1 \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1<\/th>\n<th>\u039a\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2 \u03b5\u03be\u03ad\u03bb\u03b9\u03be\u03b7\u03c2<\/th>\n<th>\u03a3\u03c4\u03c1\u03b1\u03c4\u03b7\u03b3\u03b9\u03ba\u03ae<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>MGUS<\/strong><\/td>\n<td>M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u03c7\u03b1\u03bc\u03b7\u03bb\u03ae, <em>BMPC<\/em> &lt;10%, \u03c7\u03c9\u03c1\u03af\u03c2 SLiM-CRAB<\/td>\n<td>~1%\/\u03ad\u03c4\u03bf\u03c2 (\u03bc\u03ad\u03c3\u03bf\u03c2 \u03cc\u03c1\u03bf\u03c2), \u03b1\u03bd\u03ac\u03bb\u03bf\u03b3\u03b1 \u03bc\u03b5 \u03c5\u03c0\u03bf\u03c4\u03cd\u03c0\u03bf &amp; \u03b2\u03b9\u03bf\u03b4\u03b5\u03af\u03ba\u03c4\u03b5\u03c2<\/td>\n<td>\u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7 \u03b1\u03bd\u03ac 6\u201312 \u03bc\u03ae\u03bd\u03b5\u03c2<\/td>\n<\/tr>\n<tr>\n<td><strong>SMM<\/strong><\/td>\n<td>M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u22653 g\/dL \u03ae\/\u03ba\u03b1\u03b9 <em>BMPC<\/em> 10\u201359%, \u03c7\u03c9\u03c1\u03af\u03c2 \u03b2\u03bb\u03ac\u03b2\u03b7 \u03bf\u03c1\u03b3\u03ac\u03bd\u03c9\u03bd<\/td>\n<td>\u039a\u03b1\u03c4\u03ac IMWG <em>2\/20\/20<\/em> &amp; \u03b5\u03c0\u03b5\u03ba\u03c4\u03ac\u03c3\u03b5\u03b9\u03c2: \u03c5\u03c0\u03bf\u03bf\u03bc\u03ac\u03b4\u03b5\u03c2 \u03bc\u03b5 \u226550% 2-\u03b5\u03c4\u03ae \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf<\/td>\n<td>\u03a3\u03c4\u03bf\u03c7\u03b5\u03c5\u03bc\u03ad\u03bd\u03b7 \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7\u00b7 \u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ad\u03c2 \u03b4\u03bf\u03ba\u03b9\u03bc\u03ad\u03c2 \u03b3\u03b9\u03b1 high-risk<\/td>\n<\/tr>\n<tr>\n<td><strong>MM<\/strong><\/td>\n<td>SLiM-CRAB (+\/\u2212 M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7), \u03b5\u03bd\u03b5\u03c1\u03b3\u03cc\u03c2 \u03bd\u03cc\u03c3\u03bf\u03c2<\/td>\n<td>\u03a7\u03c9\u03c1\u03af\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u2192 \u03b5\u03be\u03ad\u03bb\u03b9\u03be\u03b7\/\u03b2\u03bb\u03ac\u03b2\u03b5\u03c2\u00b7 \u03bc\u03b5 \u03c3\u03cd\u03b3\u03c7\u03c1\u03bf\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b5\u03c0\u03b9\u03bc\u03b7\u03ba\u03cd\u03bd\u03b5\u03c4\u03b1\u03b9 \u03b7 OS<\/td>\n<td>\u0386\u03bc\u03b5\u03c3\u03b7 \u03ad\u03bd\u03b1\u03c1\u03be\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03b2\u03ac\u03c3\u03b5\u03b9 fitness\/\u03b2\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03bf\u03cd \u03ba\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"kb small\"><strong>\u03a3\u03b7\u03bc\u03b5\u03af\u03c9\u03c3\u03b7:<\/strong> \u03a4\u03bf IMWG \u03bc\u03bf\u03bd\u03c4\u03ad\u03bb\u03bf <em>2\/20\/20<\/em> \u03b3\u03b9\u03b1 SMM \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b5\u03af: M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 &gt;2 g\/dL, \u03b1\u03bd\u03b1\u03bb\u03bf\u03b3\u03af\u03b1 FLC &gt;20, BMPC &gt;20%. \u03a3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03c4\u03b9\u03ba\u03ac\/\u03bc\u03b5 FISH, \u03b4\u03b9\u03b1\u03c3\u03c4\u03c1\u03c9\u03bc\u03b1\u03c4\u03ce\u03bd\u03b5\u03b9 \u03b1\u03ba\u03c1\u03b9\u03b2\u03ad\u03c3\u03c4\u03b5\u03c1\u03b1 \u03c4\u03bf\u03bd 2-\u03b5\u03c4\u03ae \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf.<\/div>\n<p><!-- ========================= SECTION 3 ========================= --><\/p>\n<h2 id=\"sec-3\" class=\"anchor\">3) \u039a\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 \u0394\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2 (IMWG): SLiM-CRAB<\/h2>\n<p>\u0397 IMWG (2014-\u03c3\u03ae\u03bc\u03b5\u03c1\u03b1) \u03b4\u03b9\u03b5\u03cd\u03c1\u03c5\u03bd\u03b5 \u03c4\u03b1 \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 \u03b5\u03bd\u03b5\u03c1\u03b3\u03bf\u03cd \u03bc\u03c5\u03b5\u03bb\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2 \u03c0\u03c1\u03bf\u03c3\u03b8\u03ad\u03c4\u03bf\u03bd\u03c4\u03b1\u03c2 \u03c4\u03c1\u03b5\u03b9\u03c2 <em>\u03b2\u03b9\u03bf\u03b4\u03b5\u03af\u03ba\u03c4\u03b5\u03c2-\u03bf\u03c1\u03b9\u03bf\u03b8\u03ad\u03c4\u03b5\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<\/em> (SLiM) \u03c3\u03b5 \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc \u03bc\u03b5 \u03c4\u03b1 \u03ba\u03bb\u03b1\u03c3\u03b9\u03ba\u03ac CRAB:<\/p>\n<div class=\"table-scroll\">\n<table>\n<thead>\n<tr>\n<th>\u03a3\u03c4\u03bf\u03b9\u03c7\u03b5\u03af\u03bf<\/th>\n<th>\u03a0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ae (\u03ad\u03bd\u03b1 \u03b1\u03c0\u03cc \u03c4\u03b1 \u03c0\u03b1\u03c1\u03b1\u03ba\u03ac\u03c4\u03c9 \u03b1\u03c1\u03ba\u03b5\u03af)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>S<\/strong> (Sixty)<\/td>\n<td>\u039a\u03bb\u03c9\u03bd\u03b9\u03ba\u03ac \u03c0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03cd\u03c4\u03c4\u03b1\u03c1\u03b1 \u03bc\u03c5\u03b5\u03bb\u03bf\u03cd \u2265 <strong>60%<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>Li<\/strong> (Light chains)<\/td>\n<td>\u0391\u03bd\u03b1\u03bb\u03bf\u03b3\u03af\u03b1 \u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7\u03c2\/\u03bc\u03b7 \u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7\u03c2 FLC \u2265 <strong>100<\/strong> <span class=\"small\">(\u03ba\u03b1\u03b9 \u03b5\u03bc\u03c0\u03bb\u03b5\u03ba\u03cc\u03bc\u03b5\u03bd\u03b7 \u2265100 mg\/L)<\/span><\/td>\n<\/tr>\n<tr>\n<td><strong>M<\/strong> (MRI)<\/td>\n<td>\u2265 <strong>1\u20132 \u03b5\u03c3\u03c4\u03b9\u03b1\u03ba\u03ad\u03c2 \u03b2\u03bb\u03ac\u03b2\u03b5\u03c2<\/strong> (IMWG: &gt;1) \u03c3\u03b5 <em>MRI<\/em> \u03bc\u03b5\u03b3\u03ad\u03b8\u03bf\u03c5\u03c2 \u22655 mm<\/td>\n<\/tr>\n<tr>\n<td><strong>C<\/strong> (Calcium)<\/td>\n<td>\u039f\u03bb. \u03b1\u03c3\u03b2\u03ad\u03c3\u03c4\u03b9\u03bf &gt;0,25 mmol\/L (&gt;1 mg\/dL) \u03c0\u03ac\u03bd\u03c9 \u03b1\u03c0\u03cc \u03c4\u03bf \u03b1\u03bd\u03ce\u03c4\u03b5\u03c1\u03bf \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc \u03ae &gt;2,75 mmol\/L (&gt;11 mg\/dL)<\/td>\n<\/tr>\n<tr>\n<td><strong>R<\/strong> (Renal)<\/td>\n<td>eGFR &lt;40 mL\/min \u03ae \u03ba\u03c1\u03b5\u03b1\u03c4\u03b9\u03bd\u03af\u03bd\u03b7 &gt;2 mg\/dL (\u03b5\u03c6\u03cc\u03c3\u03bf\u03bd \u03b1\u03c0\u03bf\u03b4\u03af\u03b4\u03b5\u03c4\u03b1\u03b9 \u03c3\u03c4\u03b7 \u03bd\u03cc\u03c3\u03bf)<\/td>\n<\/tr>\n<tr>\n<td><strong>A<\/strong> (Anemia)<\/td>\n<td>Hb &lt;10 g\/dL \u03ae &gt;2 g\/dL \u03ba\u03ac\u03c4\u03c9 \u03b1\u03c0\u03cc \u03c4\u03bf \u03ba\u03b1\u03c4\u03ce\u03c4\u03b5\u03c1\u03bf \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc<\/td>\n<\/tr>\n<tr>\n<td><strong>B<\/strong> (Bone)<\/td>\n<td>\u039f\u03c3\u03c4\u03b5\u03bf\u03bb\u03cd\u03c3\u03b5\u03b9\u03c2\/\u03bf\u03c3\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b2\u03bb\u03ac\u03b2\u03b5\u03c2 \u03c3\u03b5 LD-WBCT\/PET-CT\/MRI<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"infobox neutral\">\n<h4>\u03a3\u03cd\u03b3\u03c7\u03c1\u03bf\u03bd\u03b7 \u03b1\u03c0\u03b5\u03b9\u03ba\u03cc\u03bd\u03b9\u03c3\u03b7<\/h4>\n<p>\u0397 <strong>low-dose whole-body CT<\/strong> (LD-WBCT) \u03b5\u03af\u03bd\u03b1\u03b9 \u03c0\u03bb\u03ad\u03bf\u03bd \u03c0\u03c1\u03bf\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03b7 \u03c9\u03c2 \u03b1\u03c1\u03c7\u03b9\u03ba\u03ae \u03b5\u03be\u03ad\u03c4\u03b1\u03c3\u03b7 \u03b3\u03b9\u03b1 \u03bf\u03c3\u03c4\u03b9\u03ba\u03ae \u03bd\u03cc\u03c3\u03bf\u00b7 MRI\/PET-CT \u03c3\u03c5\u03bc\u03c0\u03bb\u03b7\u03c1\u03ce\u03bd\u03bf\u03c5\u03bd\/\u03b5\u03be\u03b5\u03b9\u03b4\u03b9\u03ba\u03b5\u03cd\u03bf\u03c5\u03bd \u03c4\u03b7 \u03c3\u03c4\u03b1\u03b4\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03ba\u03b1\u03b9 \u03c4\u03b7\u03bd \u03b5\u03ba\u03c4\u03af\u03bc\u03b7\u03c3\u03b7 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7\u03c2 (<em>imaging-MRD<\/em>).<\/p>\n<\/div>\n<p><!-- ========================= SECTION 4 ========================= --><\/p>\n<h2 id=\"sec-4\" class=\"anchor\">4) \u0394\u03b9\u03b1\u03b3\u03bd\u03c9\u03c3\u03c4\u03b9\u03ba\u03cc\u03c2 \u0388\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2<\/h2>\n<h3>4.1 \u0395\u03c1\u03b3\u03b1\u03c3\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ac<\/h3>\n<ul>\n<li>\u0397\u03bb\u03b5\u03ba\u03c4\u03c1\u03bf\u03c6\u03cc\u03c1\u03b7\u03c3\u03b7 \u03c0\u03c1\u03c9\u03c4\u03b5\u03ca\u03bd\u03ce\u03bd \u03bf\u03c1\u03bf\u03cd (SPEP) &amp; \u03b1\u03bd\u03bf\u03c3\u03bf\u03b7\u03bb\u03b5\u03ba\u03c4\u03c1\u03bf\u03c6\u03cc\u03c1\u03b7\u03c3\u03b7 (IFE)<\/li>\n<li>\u039f\u03cd\u03c1\u03b1 24\u03ce\u03c1\u03bf\u03c5: UPEP\/IFE (Bence-Jones)<\/li>\n<li>\u03a0\u03bf\u03c3\u03bf\u03c4\u03b9\u03ba\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 FLC (\u03ba\/\u03bb) \u03ba\u03b1\u03b9 \u03b1\u03bd\u03b1\u03bb\u03bf\u03b3\u03af\u03b1<\/li>\n<li>\u0392\u03b1\u03c3\u03b9\u03ba\u03ae \u03b1\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae (Hb, WBC, PLT), \u03b2\u03b9\u03bf\u03c7\u03b7\u03bc\u03b9\u03ba\u03cc\u03c2 \u03ad\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2 (Ca, \u03bf\u03c5\u03c1\u03af\u03b1\/\u03ba\u03c1\u03b5\u03b1\u03c4\u03b9\u03bd\u03af\u03bd\u03b7\/eGFR, \u03bb\u03b5\u03c5\u03ba\u03c9\u03bc\u03b1\u03c4\u03af\u03bd\u03b7, LDH), \u03b22-\u03bc\u03b9\u03ba\u03c1\u03bf\u03c3\u03c6\u03b1\u03b9\u03c1\u03af\u03bd\u03b7<\/li>\n<li>\u039c\u03c5\u03b5\u03bb\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1\/\u03b2\u03b9\u03bf\u03c8\u03af\u03b1 \u03bc\u03c5\u03b5\u03bb\u03bf\u03cd \u03bc\u03b5 <em>\u03bc\u03bf\u03c1\u03c6\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/em>, <em>\u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03bf\u03bc\u03b5\u03c4\u03c1\u03af\u03b1 \u03c1\u03bf\u03ae\u03c2<\/em>, <em>FISH<\/em> (del(17p), t(4;14), t(14;16), +1q \u03ba.\u03ac.)<\/li>\n<\/ul>\n<h3>4.2 \u0391\u03c0\u03b5\u03b9\u03ba\u03cc\u03bd\u03b9\u03c3\u03b7 (\u03c0\u03c1\u03ce\u03c4\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae &amp; \u03b5\u03be\u03b5\u03b9\u03b4\u03b9\u03ba\u03b5\u03c5\u03bc\u03ad\u03bd\u03b7)<\/h3>\n<ul>\n<li><strong>LD-WBCT<\/strong>: \u03c5\u03c8\u03b7\u03bb\u03ae \u03b5\u03c5\u03b1\u03b9\u03c3\u03b8\u03b7\u03c3\u03af\u03b1 \u03b3\u03b9\u03b1 \u03bf\u03c3\u03c4\u03b5\u03bf\u03bb\u03cd\u03c3\u03b5\u03b9\u03c2, \u03b1\u03bd\u03c4\u03b9\u03ba\u03b1\u03b8\u03b9\u03c3\u03c4\u03ac \u03c4\u03bf \u03ba\u03bb\u03b1\u03c3\u03b9\u03ba\u03cc skeletal survey.<\/li>\n<li><strong>PET-CT<\/strong>: \u03b4\u03c1\u03b1\u03c3\u03c4\u03b7\u03c1\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1 \u03bd\u03cc\u03c3\u03bf\u03c5\/metabolic burden, \u03c7\u03c1\u03ae\u03c3\u03b9\u03bc\u03b7 \u03c3\u03b5 \u03b1\u03bc\u03c6\u03af\u03b2\u03bf\u03bb\u03b5\u03c2 \u03c0\u03b5\u03c1\u03b9\u03c0\u03c4\u03ce\u03c3\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03c3\u03c4\u03b7\u03bd \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7.<\/li>\n<li><strong>WB-MRI<\/strong>: \u03b1\u03bd\u03ce\u03c4\u03b5\u03c1\u03b7 \u03b3\u03b9\u03b1 \u03bc\u03c5\u03b5\u03bb\u03b9\u03ba\u03ac \u03b4\u03b9\u03b7\u03b8\u03ae\u03bc\u03b1\u03c4\u03b1\/\u03b5\u03c3\u03c4\u03b9\u03b1\u03ba\u03ad\u03c2 \u03b2\u03bb\u03ac\u03b2\u03b5\u03c2 \u03c7\u03c9\u03c1\u03af\u03c2 \u03bf\u03c3\u03c4\u03b9\u03ba\u03ae \u03ba\u03b1\u03c4\u03b1\u03c3\u03c4\u03c1\u03bf\u03c6\u03ae.<\/li>\n<\/ul>\n<h3>4.3 \u0395\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf \u03a5\u03c0\u03bf\u03bb\u03b5\u03b9\u03bc\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc \u039d\u03cc\u03c3\u03b7\u03bc\u03b1 (MRD)<\/h3>\n<ul>\n<li><em>Next-Generation Flow<\/em> \u03ae <em>Next-Generation Sequencing<\/em> (\u03b5\u03c5\u03b1\u03b9\u03c3\u03b8\u03b7\u03c3\u03af\u03b1 \u226510<sup>\u22125<\/sup>), \u03c3\u03c5\u03bc\u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03ac imaging-MRD (PET-CT).<\/li>\n<li><span class=\"small\">\u0397 \u00ab\u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03c4\u03b1\u03bc\u03ad\u03bd\u03b7 MRD-\u03b1\u03c1\u03bd\u03b7\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1\u00bb \u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b5 \u03b4\u03cd\u03bf \u03bc\u03b5\u03c4\u03c1\u03ae\u03c3\u03b5\u03b9\u03c2 \u22651 \u03ad\u03c4\u03bf\u03c2 \u03bc\u03b5\u03c4\u03b1\u03be\u03cd \u03c4\u03bf\u03c5\u03c2, \u03ba\u03b1\u03b9 \u03c3\u03c5\u03c3\u03c7\u03b5\u03c4\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b5 \u03b2\u03b5\u03bb\u03c4\u03b9\u03c9\u03bc\u03ad\u03bd\u03b7 \u03ad\u03ba\u03b2\u03b1\u03c3\u03b7.<\/span><\/li>\n<\/ul>\n<p><!-- ========================= SECTION 5 ========================= --><\/p>\n<h2 id=\"sec-5\" class=\"anchor\">5) \u03a3\u03c4\u03b1\u03b4\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 &amp; \u0392\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc\u03c2 \u039a\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2: ISS, R-ISS, R2-ISS<\/h2>\n<div class=\"table-scroll\">\n<table>\n<thead>\n<tr>\n<th>\u03a3\u03cd\u03c3\u03c4\u03b7\u03bc\u03b1<\/th>\n<th>\u039c\u03b5\u03c4\u03b1\u03b2\u03bb\u03b7\u03c4\u03ad\u03c2<\/th>\n<th>\u039a\u03b1\u03c4\u03b7\u03b3\u03bf\u03c1\u03af\u03b5\u03c2\/\u03a3\u03b7\u03bc\u03b1\u03c3\u03af\u03b1<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>ISS<\/strong><\/td>\n<td>\u03b2<sub>2<\/sub>-\u03bc\u03b9\u03ba\u03c1\u03bf\u03c3\u03c6\u03b1\u03b9\u03c1\u03af\u03bd\u03b7, \u03bb\u03b5\u03c5\u03ba\u03c9\u03bc\u03b1\u03c4\u03af\u03bd\u03b7<\/td>\n<td>\u0392\u03b1\u03c3\u03b9\u03ba\u03ae \u03c0\u03c1\u03cc\u03b3\u03bd\u03c9\u03c3\u03b7 \u03bc\u03b5 \u03b2\u03ac\u03c3\u03b7 burden\/\u03b8\u03c1\u03ad\u03c8\u03b7<\/td>\n<\/tr>\n<tr>\n<td><strong>R-ISS<\/strong><\/td>\n<td>ISS + LDH + \u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03bf\u03b3\u03b5\u03bd\u03b5\u03c4\u03b9\u03ba\u03ae (del17p, t(4;14), t(14;16))<\/td>\n<td>\u039a\u03b1\u03bb\u03cd\u03c4\u03b5\u03c1\u03b7 \u03b4\u03b9\u03b1\u03c3\u03c4\u03c1\u03c9\u03bc\u03ac\u03c4\u03c9\u03c3\u03b7 \u03c5\u03c8\u03b7\u03bb\u03bf\u03cd \u03ba\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5<\/td>\n<\/tr>\n<tr>\n<td><strong>R2-ISS<\/strong><\/td>\n<td>R-ISS + <strong>+1q<\/strong> (gain\/amp) \u03ba\u03b1\u03b9 \u03b2\u03b1\u03b8\u03bc\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7 \u03c3\u03b7\u03bc\u03b5\u03af\u03c9\u03bd<\/td>\n<td>4 \u03c3\u03c4\u03ac\u03b4\u03b9\u03b1\u00b7 \u03b2\u03b5\u03bb\u03c4\u03b9\u03c9\u03bc\u03ad\u03bd\u03b7 \u03c0\u03c1\u03cc\u03b3\u03bd\u03c9\u03c3\u03b7 \u03b5\u03b9\u03b4\u03b9\u03ba\u03ac \u03c3\u03c4\u03b9\u03c2 \u03b5\u03bd\u03b4\u03b9\u03ac\u03bc\u03b5\u03c3\u03b5\u03c2 \u03bf\u03bc\u03ac\u03b4\u03b5\u03c2<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"infobox neutral\">\n<h4>\u0393\u03b9\u03b1\u03c4\u03af \u03bc\u03b5\u03c4\u03c1\u03ac;<\/h4>\n<p>\u039f \u03b2\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc\u03c2 \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2 (\u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03bf\u03b3\u03b5\u03bd\u03b5\u03c4\u03b9\u03ba\u03ae, +1q) \u03ba\u03b1\u03b9 \u03b4\u03b5\u03af\u03ba\u03c4\u03b5\u03c2 \u03cc\u03c0\u03c9\u03c2 LDH \u03ba\u03b1\u03b8\u03bf\u03b4\u03b7\u03b3\u03bf\u03cd\u03bd \u03ad\u03bd\u03c4\u03b1\u03c3\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2, \u03b5\u03c0\u03b9\u03bb\u03bf\u03b3\u03ae \u03c3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7\u03c2 \u03ba\u03b1\u03b9 \u03c3\u03c5\u03c7\u03bd\u03cc\u03c4\u03b7\u03c4\u03b1 \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7\u03c2.<\/p>\n<\/div>\n<p><!-- ========================= SECTION 6 ========================= --><\/p>\n<h2 id=\"sec-6\" class=\"anchor\">6) \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u0395\u03b9\u03ba\u03cc\u03bd\u03b1 &amp; \u0395\u03c0\u03b9\u03c0\u03bb\u03bf\u03ba\u03ad\u03c2<\/h2>\n<ul>\n<li><strong>\u039f\u03c3\u03c4\u03ac<\/strong>: \u03bb\u03c5\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b2\u03bb\u03ac\u03b2\u03b5\u03c2, \u03ba\u03b1\u03c4\u03ac\u03b3\u03bc\u03b1\u03c4\u03b1, \u03c3\u03c0\u03bf\u03bd\u03b4\u03c5\u03bb\u03b9\u03ba\u03ac \u03c3\u03c5\u03bc\u03c0\u03b9\u03b5\u03c3\u03c4\u03b9\u03ba\u03ac\u00b7 \u03b1\u03bd\u03c4\u03b9\u03bc\u03b5\u03c4\u03ce\u03c0\u03b9\u03c3\u03b7 \u03bc\u03b5 \u03b1\u03bd\u03b1\u03bb\u03b3\u03b7\u03c3\u03af\u03b1, \u03b1\u03ba\u03c4\u03b9\u03bd\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\/\u03ba\u03c5\u03c6\u03bf\u03c0\u03bb\u03b1\u03c3\u03c4\u03b9\u03ba\u03ae, <em>\u03b6\u03bf\u03bb\u03b5\u03b4\u03c1\u03bf\u03bd\u03b9\u03ba\u03cc\/\u03c0\u03b1\u03bc\u03b9\u03b4\u03c1\u03bf\u03bd\u03b9\u03ba\u03cc<\/em> \u03ae <em>\u03bd\u03c4\u03b5\u03bd\u03bf\u03c3\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7<\/em>\u00b7 \u03c0\u03c1\u03cc\u03bb\u03b7\u03c8\u03b7 MRONJ (\u03c3\u03c4\u03bf\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03b3\u03b5\u03af\u03b1).<\/li>\n<li><strong>\u03a5\u03c0\u03b5\u03c1\u03b1\u03c3\u03b2\u03b5\u03c3\u03c4\u03b9\u03b1\u03b9\u03bc\u03af\u03b1<\/strong>: \u03b5\u03bd\u03c5\u03b4\u03ac\u03c4\u03c9\u03c3\u03b7, IV \u03b4\u03b9\u03c6\u03c9\u03c3\u03c6\u03bf\u03bd\u03b9\u03ba\u03cc <em>\u03ae<\/em> \u03bd\u03c4\u03b5\u03bd\u03bf\u03c3\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7\u00b7 \u03c3\u03b5 \u03c3\u03bf\u03b2\u03b1\u03c1\u03ae, \u03c0\u03c1\u03bf\u03c3\u03b8\u03ae\u03ba\u03b7 \u03ba\u03b1\u03bb\u03c3\u03b9\u03c4\u03bf\u03bd\u03af\u03bd\u03b7\u03c2 \u03b3\u03b9\u03b1 48\u201372 \u03ce\u03c1\u03b5\u03c2.<\/li>\n<li><strong>\u039d\u03b5\u03c6\u03c1\u03ac<\/strong>: cast nephropathy, FLC-\u03bd\u03b5\u03c6\u03c1\u03bf\u03c0\u03ac\u03b8\u03b5\u03b9\u03b1\u00b7 \u03ac\u03bc\u03b5\u03c3\u03b7 \u03ad\u03bd\u03b1\u03c1\u03be\u03b7 <em>bortezomib-based<\/em> \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 + \u03c5\u03c8\u03b7\u03bb\u03ae \u03b4\u03cc\u03c3\u03b7 \u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7\u03c2, \u03b5\u03c0\u03b9\u03b8\u03b5\u03c4\u03b9\u03ba\u03ae \u03b5\u03bd\u03c5\u03b4\u03ac\u03c4\u03c9\u03c3\u03b7\u00b7 \u03c0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ae \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03b9\u03ce\u03bd (IMiDs).<\/li>\n<li><strong>\u0391\u03bd\u03b1\u03b9\u03bc\u03af\u03b1<\/strong>: \u03c0\u03bf\u03bb\u03c5\u03c0\u03b1\u03c1\u03b1\u03b3\u03bf\u03bd\u03c4\u03b9\u03ba\u03ae\u00b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bd\u03cc\u03c3\u03bf\u03c5, \u03c3\u03b9\u03b4\u03b7\u03c1\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\/\u03b2\u03b9\u03c4\u03b1\u03bc\u03af\u03bd\u03b5\u03c2 \u03ba\u03b1\u03c4\u03ac \u03ad\u03bd\u03b4\u03b5\u03b9\u03be\u03b7, EPO \u03c3\u03b5 \u03b5\u03c0\u03b9\u03bb\u03b5\u03b3\u03bc\u03ad\u03bd\u03bf\u03c5\u03c2.<\/li>\n<li><strong>\u039b\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2<\/strong>: \u03b5\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03bf\u03af (Influenza, Pneumococcal, Recombinant Zoster), \u03b1\u03bd\u03c4\u03b9-\u03b9\u03b9\u03ba\u03ae \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7 \u03b3\u03b9\u03b1 VZV \u03c3\u03b5 PI\/anti-CD38, \u00b1 PJP \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7 \u03c3\u03b5 \u03c5\u03c8\u03b7\u03bb\u03cc \u03c1\u03af\u03c3\u03ba\u03bf, IVIG \u03c3\u03b5 \u03c5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03b9\u03ac\u03b6\u03bf\u03c5\u03c3\u03b5\u03c2 \u03bb\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2.<\/li>\n<\/ul>\n<p><!-- ========================= SECTION 7 ========================= --><\/p>\n<h2 id=\"sec-7\" class=\"anchor\">7) \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03a0\u03c1\u03ce\u03c4\u03b7\u03c2 \u0393\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2 (NDMM)<\/h2>\n<div class=\"infobox success\">\n<h4>High-level \u03c0\u03bb\u03b1\u03af\u03c3\u03b9\u03bf<\/h4>\n<ul>\n<li><strong>\u03a5\u03c0\u03bf\u03c8\u03ae\u03c6\u03b9\u03bf\u03b9 \u03b3\u03b9\u03b1 ASCT<\/strong>: Quadruplet \u03bc\u03b5 <em>daratumumab + VRd<\/em> (D-VRd) \u03c9\u03c2 \u03c0\u03c1\u03bf\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf, \u03c3\u03c4\u03b7 \u03c3\u03c5\u03bd\u03ad\u03c7\u03b5\u03b9\u03b1 <em>ASCT<\/em> \u03ba\u03b1\u03b9 \u03c3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7.<\/li>\n<li><strong>\u039c\u03b7 \u03c5\u03c0\u03bf\u03c8\u03ae\u03c6\u03b9\u03bf\u03b9\/\u03b7\u03bb\u03b9\u03ba\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf\u03b9\/frail<\/strong>: <em>DRd<\/em> \u03ae \u03c0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03c3\u03bc\u03ad\u03bd\u03bf <em>VRd-lite<\/em>, \u03bc\u03b5 \u03ad\u03bc\u03c6\u03b1\u03c3\u03b7 \u03c3\u03c4\u03b7\u03bd \u03b1\u03bd\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c3\u03b5 <em>dose-dext<\/em> \u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7.<\/li>\n<\/ul>\n<\/div>\n<h3>7.1 \u03a5\u03c0\u03bf\u03c8\u03ae\u03c6\u03b9\u03bf\u03b9 \u03b3\u03b9\u03b1 \u03bc\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7 (ASCT)<\/h3>\n<ul>\n<li><strong>D-VRd<\/strong> (daratumumab + bortezomib + lenalidomide + dex): preferred \u03c0\u03c1\u03ce\u03c4\u03b7 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae \u03c3\u03b5 \u03ba\u03b1\u03c4\u03b5\u03c5\u03b8\u03c5\u03bd\u03c4\u03ae\u03c1\u03b9\u03b5\u03c2\u00b7 <em>induction \u2192 stem cell harvest \u2192 HD melphalan + ASCT \u2192 (\u00b1 consolidation) \u2192 maintenance<\/em>.<\/li>\n<li>\u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ac \u03c4\u03c1\u03b9\u03c0\u03bb\u03ad\u03c4\u03b5\u03c2 \u03c5\u03c8\u03b7\u03bb\u03ae\u03c2 \u03ad\u03bd\u03c4\u03b1\u03c3\u03b7\u03c2 (\u03c0.\u03c7. <em>KRd<\/em>) \u03b1\u03bd\u03ac \u03ba\u03ad\u03bd\u03c4\u03c1\u03bf\/\u03c0\u03c1\u03c9\u03c4\u03cc\u03ba\u03bf\u03bb\u03bb\u03b1.<\/li>\n<\/ul>\n<h3>7.2 \u039c\u03b7 \u03c5\u03c0\u03bf\u03c8\u03ae\u03c6\u03b9\u03bf\u03b9 \u03b3\u03b9\u03b1 \u03bc\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7<\/h3>\n<ul>\n<li><strong>DRd<\/strong> (daratumumab + lenalidomide + dex): \u03b9\u03c3\u03c7\u03c5\u03c1\u03ae, \u03b1\u03bd\u03b5\u03ba\u03c4\u03ae \u03b5\u03c0\u03b9\u03bb\u03bf\u03b3\u03ae \u03c0\u03c1\u03ce\u03c4\u03b7\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2.<\/li>\n<li><strong>VRd-lite<\/strong>: \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 \u03b4\u03cc\u03c3\u03b5\u03c9\u03bd\/\u03c3\u03c5\u03c7\u03bd\u03bf\u03c4\u03ae\u03c4\u03c9\u03bd \u03b3\u03b9\u03b1 \u03b5\u03c5\u03b8\u03c1\u03b1\u03c5\u03c3\u03c4\u03cc\u03c4\u03b7\u03c4\u03b1, \u03b4\u03b9\u03b1\u03c4\u03b7\u03c1\u03ce\u03bd\u03c4\u03b1\u03c2 \u03b1\u03c0\u03bf\u03c4\u03b5\u03bb\u03b5\u03c3\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1.<\/li>\n<li><em>Frailty-adjusted<\/em> \u03c3\u03c7\u03ae\u03bc\u03b1\u03c4\u03b1: \u03b5\u03be\u03b1\u03c4\u03bf\u03bc\u03af\u03ba\u03b5\u03c5\u03c3\u03b7 \u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7\u03c2 (\u03c3\u03c5\u03c7\u03bd\u03ac \u226420 mg\/\u03b5\u03b2\u03b4.) \u03ba\u03b1\u03b9 IMiD\/PI.<\/li>\n<\/ul>\n<div class=\"kb small\"><strong>\u03a3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7 (preview):<\/strong> \u039c\u03b5\u03c4\u03ac ASCT, <em>lenalidomide<\/em> \u03b2\u03b5\u03bb\u03c4\u03b9\u03ce\u03bd\u03b5\u03b9 PFS\/OS\u00b7 \u03c3\u03b5 standard-risk \u03ba\u03b1\u03b9 \u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03c4\u03b1\u03bc\u03ad\u03bd\u03b7 MRD-(\u2013) \u03c3\u03c5\u03b6\u03b7\u03c4\u03b5\u03af\u03c4\u03b1\u03b9 \u03b4\u03b9\u03b1\u03ba\u03bf\u03c0\u03ae \u03bc\u03b5\u03c4\u03ac \u22653 \u03ad\u03c4\u03b7 (\u03c5\u03c0\u03cc \u03c4\u03b5\u03ba\u03bc\u03b7\u03c1\u03af\u03c9\u03c3\u03b7). \u03a3\u03b5 high-risk, \u03c0\u03c1\u03bf\u03c3\u03c4\u03af\u03b8\u03b5\u03bd\u03c4\u03b1\u03b9 \u03c3\u03c4\u03c1\u03b1\u03c4\u03b7\u03b3\u03b9\u03ba\u03ad\u03c2 \u03b5\u03bd\u03af\u03c3\u03c7\u03c5\u03c3\u03b7\u03c2 (\u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03bf\u03af\/PI), \u03b5\u03be\u03b1\u03c4\u03bf\u03bc\u03b9\u03ba\u03b5\u03c5\u03bc\u03ad\u03bd\u03b1.<\/div>\n<p><!-- ========================= \u03a0\u039f\u039b\u039b\u0391\u03a0\u039b\u039f \u039c\u03a5\u0395\u039b\u03a9\u039c\u0391 \u2013 \u039f\u0394\u0397\u0393\u039f\u03a3 (\u039c\u0395\u03a1\u039f\u03a3 \u0392: Sections 8\u201312) Mobile-friendly HTML \u03b3\u03b9\u03b1 Classic Editor ========================= --><\/p>\n<p><!-- \u039c\u03b9\u03ba\u03c1\u03cc \u03c4\u03bf\u03c0\u03b9\u03ba\u03cc TOC (\u03c0\u03c1\u03bf\u03b1\u03b9\u03c1\u03b5\u03c4\u03b9\u03ba\u03cc) --><\/p>\n<p><!-- ========================= SECTION 8 ========================= --><\/p>\n<h2 id=\"sec-8\" class=\"anchor\">8) \u0391\u03c5\u03c4\u03cc\u03bb\u03bf\u03b3\u03b7 \u039c\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7 \u0391\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b7\u03c4\u03b9\u03ba\u03ce\u03bd \u039a\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd (ASCT)<\/h2>\n<div class=\"infobox success\">\n<h4>\u03a4\u03b9 \u03ba\u03b5\u03c1\u03b4\u03af\u03b6\u03c9 \u03bc\u03b5 \u03c4\u03b7\u03bd ASCT;<\/h4>\n<p>\u03a3\u03b5 \u03ba\u03b1\u03c4\u03ac\u03bb\u03bb\u03b7\u03bb\u03bf\u03c5\u03c2 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2, \u03b7 ASCT \u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03af\u03bd\u03b5\u03b9 \u03c4\u03bf progression-free survival (PFS) \u03ba\u03b1\u03b9 \u03b1\u03c5\u03be\u03ac\u03bd\u03b5\u03b9 \u03c4\u03b1 \u03c0\u03bf\u03c3\u03bf\u03c3\u03c4\u03ac \u03b2\u03b1\u03b8\u03b9\u03ac\u03c2 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7\u03c2 (\u03c3\u03c5\u03bc\u03c0\u03b5\u03c1. MRD-\u03b1\u03c1\u03bd\u03b7\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2). \u03a0\u03b1\u03c1\u03b1\u03bc\u03ad\u03bd\u03b5\u03b9 \u00abstandard of care\u00bb \u03bc\u03b5\u03c4\u03ac \u03b1\u03c0\u03cc \u03c3\u03cd\u03b3\u03c7\u03c1\u03bf\u03bd\u03bf quadruplet induction (\u03c0.\u03c7. D-VRd).<\/p>\n<\/div>\n<h3>8.1 \u0395\u03c0\u03b9\u03bb\u03bf\u03b3\u03ae \u03a5\u03c0\u03bf\u03c8\u03b7\u03c6\u03af\u03c9\u03bd (fitness)<\/h3>\n<ul>\n<li>\u0394\u03b5\u03bd \u03b2\u03b1\u03c3\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03bf\u03ba\u03bb\u03b5\u03b9\u03c3\u03c4\u03b9\u03ba\u03ac \u03c3\u03c4\u03b7\u03bd \u03b7\u03bb\u03b9\u03ba\u03af\u03b1\u00b7 \u03b5\u03ba\u03c4\u03af\u03bc\u03b7\u03c3\u03b7 <em>\u03b2\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae\u03c2<\/em> \u03b7\u03bb\u03b9\u03ba\u03af\u03b1\u03c2\/\u03c3\u03c5\u03bd\u03bd\u03bf\u03c3\u03b7\u03c1\u03bf\u03c4\u03ae\u03c4\u03c9\u03bd \u03ba\u03b1\u03b9 <em>frailty<\/em>.<\/li>\n<li>\u0391\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2: \u03b5\u03bd\u03b5\u03c1\u03b3\u03ad\u03c2 \u03bb\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2, \u03bc\u03b7 \u03b1\u03bd\u03c4\u03b9\u03c1\u03c1\u03bf\u03c0\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03ba\u03b1\u03c1\u03b4\u03b9\u03bf\u03c0\u03bd\u03b5\u03c5\u03bc\u03bf\u03bd\u03b9\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1, \u03bc\u03b7 \u03b5\u03bb\u03b5\u03b3\u03c7\u03cc\u03bc\u03b5\u03bd\u03b7 \u03bd\u03cc\u03c3\u03bf\u03c2.<\/li>\n<li><em>Renal impairment<\/em>: ASCT \u03b4\u03c5\u03bd\u03b1\u03c4\u03ae \u03bc\u03b5 \u03c0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ae \u03bc\u03b5\u03bb\u03c6\u03b1\u03bb\u03ac\u03bd\u03b7\u03c2 (Mel200 \u2192 Mel140 \u03ba\u03b1\u03c4\u03ac \u03ad\u03bd\u03b4\u03b5\u03b9\u03be\u03b7).<\/li>\n<\/ul>\n<div class=\"table-scroll\">\n<table>\n<thead>\n<tr>\n<th>\u03a0\u03b1\u03c1\u03ac\u03bc\u03b5\u03c4\u03c1\u03bf\u03c2<\/th>\n<th>\u0395\u03ba\u03c4\u03af\u03bc\u03b7\u03c3\u03b7<\/th>\n<th>\u0395\u03c0\u03af\u03b4\u03c1\u03b1\u03c3\u03b7 \u03c3\u03c4\u03b7\u03bd \u03b1\u03c0\u03cc\u03c6\u03b1\u03c3\u03b7<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u039a\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1<\/td>\n<td>LVEF, BNP\/NT-proBNP, \u03c6\u03bf\u03c1\u03c4\u03af\u03bf \u03bd\u03cc\u03c3\u03bf\u03c5<\/td>\n<td>\u039f\u03c1\u03b9\u03b1\u03ba\u03ae \u03ba\u03b1\u03c4\u03ac\u03c3\u03c4\u03b1\u03c3\u03b7 \u2192 \u03b1\u03bd\u03b1\u03b2\u03bf\u03bb\u03ae\/\u03b2\u03b5\u03bb\u03c4\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7<\/td>\n<\/tr>\n<tr>\n<td>\u039d\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1<\/td>\n<td>eGFR, FLC-\u03bd\u03b5\u03c6\u03c1\u03bf\u03c0\u03ac\u03b8\u03b5\u03b9\u03b1<\/td>\n<td>\u03a0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ae Mel, \u03b5\u03bd\u03c5\u03b4\u03ac\u03c4\u03c9\u03c3\u03b7, \u03b1\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u03bd\u03b5\u03c6\u03c1\u03bf\u03c4\u03bf\u03be\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2<\/td>\n<\/tr>\n<tr>\n<td>\u039b\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2\/\u03b5\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03bf\u03af<\/td>\n<td>\u0388\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2 HBV\/HCV\/HIV, \u03b5\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03c4\u03b9\u03ba\u03cc status<\/td>\n<td>\u0391\u03bd\u03c4\u03b9\u03ca\u03ba\u03ae \u03ba\u03ac\u03bb\u03c5\u03c8\u03b7 \u03cc\u03c0\u03bf\u03c5 \u03b5\u03bd\u03b4\u03b5\u03af\u03ba\u03bd\u03c5\u03c4\u03b1\u03b9<\/td>\n<\/tr>\n<tr>\n<td>Frailty<\/td>\n<td>\u039a\u03bb\u03af\u03bc\u03b1\u03ba\u03b5\u03c2 frailty\/ADL<\/td>\n<td>\u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ae: \u03bc\u03b7-ASCT \u03c0\u03c1\u03bf\u03c3\u03ad\u03b3\u03b3\u03b9\u03c3\u03b7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h3>8.2 \u0392\u03b1\u03c3\u03b9\u03ba\u03ac \u0392\u03ae\u03bc\u03b1\u03c4\u03b1 \u0394\u03b9\u03b1\u03b4\u03b9\u03ba\u03b1\u03c3\u03af\u03b1\u03c2<\/h3>\n<ol>\n<li><strong>Induction<\/strong> (\u03c3\u03c5\u03bd\u03ae\u03b8\u03c9\u03c2 4 \u03ba\u03cd\u03ba\u03bb\u03bf\u03b9 D-VRd \u03ae \u03b9\u03c3\u03bf\u03b4\u03cd\u03bd\u03b1\u03bc\u03bf).<\/li>\n<li><strong>\u039a\u03b9\u03bd\u03b7\u03c4\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7<\/strong> CD34<sup>+<\/sup> \u03bc\u03b5 G-CSF \u00b1 \u03c0\u03bb\u03b5\u03c1\u03b9\u03be\u03b1\u03c6\u03cc\u03c1\u03b7\u00b7 \u03c3\u03c4\u03cc\u03c7\u03bf\u03c2 \u22652\u20134\u00d710<sup>6<\/sup>\/kg.<\/li>\n<li><strong>\u03a3\u03c5\u03bb\u03bb\u03bf\u03b3\u03ae<\/strong> (\u03b1\u03c6\u03b1\u03af\u03c1\u03b5\u03c3\u03b7\/\u03b1\u03c6\u03b1\u03af\u03c1\u03b5\u03c3\u03b7 \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03ce\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03b1\u03bd \u03c7\u03c1\u03b5\u03b9\u03b1\u03c3\u03c4\u03b5\u03af).<\/li>\n<li><strong>\u03a5\u03c8\u03b7\u03bb\u03ae \u03b4\u03cc\u03c3\u03b7 \u03bc\u03b5\u03bb\u03c6\u03b1\u03bb\u03ac\u03bd\u03b7\u03c2<\/strong> (Mel200 \u03ae Mel140).<\/li>\n<li><strong>\u0388\u03b3\u03c7\u03c5\u03c3\u03b7<\/strong> \u03bc\u03bf\u03c3\u03c7\u03b5\u03cd\u03bc\u03b1\u03c4\u03bf\u03c2 (day 0).<\/li>\n<li><strong>\u03a5\u03c0\u03bf\u03c3\u03c4\u03ae\u03c1\u03b9\u03be\u03b7<\/strong>: \u03b1\u03bd\u03c4\u03b9\u03b5\u03bc\u03b5\u03c4\u03b9\u03ba\u03ac, G-CSF, \u03b1\u03bd\u03c4\u03b9\u03bc\u03b9\u03ba\u03c1\u03bf\u03b2\u03b9\u03b1\u03ba\u03ae \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7, \u03bc\u03b5\u03c4\u03b1\u03b3\u03b3\u03af\u03c3\u03b5\u03b9\u03c2.<\/li>\n<li><strong>Engraftment<\/strong>: \u03bf\u03c5\u03b4\u03b5\u03c4\u03b5\u03c1\u03bf\u03c6\u03b9\u03bb\u03af\u03b1 ~day +10 \u03ad\u03c9\u03c2 +14\u00b7 PLT \u03b1\u03c1\u03b3\u03cc\u03c4\u03b5\u03c1\u03b1.<\/li>\n<li><strong>\u00b1 Consolidation<\/strong> 0\u20132 \u03ba\u03cd\u03ba\u03bb\u03bf\u03b9 \u03ba\u03b1\u03c4\u03ac \u03ba\u03ad\u03bd\u03c4\u03c1\u03bf\/\u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf.<\/li>\n<li><strong>\u03a3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7<\/strong> (\u03b2\u03bb. \u00a79).<\/li>\n<\/ol>\n<div class=\"infobox neutral\">\n<h4>\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u03a4\u03bf\u03be\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b5\u03c2 &amp; \u0391\u03bd\u03c4\u03b9\u03bc\u03b5\u03c4\u03ce\u03c0\u03b9\u03c3\u03b7<\/h4>\n<ul>\n<li><strong>\u0392\u03bb\u03b5\u03bd\u03bd\u03bf\u03b3\u03bf\u03bd\u03af\u03c4\u03b9\u03b4\u03b1<\/strong> (days +3 \u03ad\u03c9\u03c2 +10): \u03b5\u03bd\u03c4\u03b1\u03c4\u03b9\u03ba\u03ae \u03c3\u03c4\u03bf\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03c6\u03c1\u03bf\u03bd\u03c4\u03af\u03b4\u03b1, \u03c0\u03b1\u03c1\u03b5\u03bd\u03c4\u03b5\u03c1\u03b9\u03ba\u03ae \u03c5\u03c0\u03bf\u03c3\u03c4\u03ae\u03c1\u03b9\u03be\u03b7, \u03b1\u03bd\u03b1\u03bb\u03b3\u03b7\u03c3\u03af\u03b1.<\/li>\n<li><strong>\u039f\u03c5\u03b4\u03b5\u03c4\u03b5\u03c1\u03bf\u03c0\u03b5\u03bd\u03b9\u03ba\u03cc\u03c2 \u03c0\u03c5\u03c1\u03b5\u03c4\u03cc\u03c2<\/strong>: \u03ba\u03b1\u03c4\u03b5\u03c5\u03b8\u03c5\u03bd\u03c4\u03ae\u03c1\u03b9\u03b5\u03c2 \u03b3\u03b9\u03b1 \u03b5\u03bc\u03c0\u03b5\u03b9\u03c1\u03b9\u03ba\u03ae \u03b1\u03bd\u03c4\u03b9\u03b2\u03af\u03c9\u03c3\u03b7, \u03ba\u03b1\u03bb\u03bb\u03b9\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2.<\/li>\n<li><strong>\u039d\u03b1\u03c5\u03c4\u03af\u03b1\/\u03ad\u03bc\u03b5\u03c4\u03bf\u03c2<\/strong>: \u03c0\u03c1\u03bf\u03c6\u03c5\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ac \u03b1\u03bd\u03c4\u03b9\u03b5\u03bc\u03b5\u03c4\u03b9\u03ba\u03ac \u03c0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03ce\u03bd \u03ba\u03b1\u03c4\u03b7\u03b3\u03bf\u03c1\u03b9\u03ce\u03bd.<\/li>\n<li><strong>\u0395\u03bc\u03c0\u03bb\u03bf\u03ba\u03ae \u03bd\u03b5\u03c6\u03c1\u03ce\u03bd<\/strong>: \u03b1\u03c5\u03c3\u03c4\u03b7\u03c1\u03ae \u03b5\u03bd\u03c5\u03b4\u03ac\u03c4\u03c9\u03c3\u03b7, \u03b1\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u03bd\u03b5\u03c6\u03c1\u03bf\u03c4\u03bf\u03be\u03b9\u03ba\u03ce\u03bd.<\/li>\n<\/ul>\n<\/div>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= SECTION 9 ========================= --><\/p>\n<h2 id=\"sec-9\" class=\"anchor\">9) \u03a3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7 (Maintenance) \u03bc\u03b5\u03c4\u03ac ASCT \u03ae \u03c7\u03c9\u03c1\u03af\u03c2 ASCT<\/h2>\n<p class=\"lead\">\u03a3\u03c4\u03cc\u03c7\u03bf\u03c2: \u03b4\u03b9\u03b1\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7 \u03b2\u03b1\u03b8\u03b9\u03ac\u03c2 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7\u03c2, \u03c0\u03b1\u03c1\u03ac\u03c4\u03b1\u03c3\u03b7 PFS\/OS \u03bc\u03b5 \u03b5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03b7 \u03b5\u03c0\u03b9\u03b2\u03ac\u03c1\u03c5\u03bd\u03c3\u03b7. \u0397 \u03b5\u03c0\u03b9\u03bb\u03bf\u03b3\u03ae \u03b5\u03c0\u03b7\u03c1\u03b5\u03ac\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03bf\u03bd <em>\u03b2\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03cc \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf<\/em> (R-ISS\/R2-ISS, +1q, del17p, t(4;14), \u03ba.\u03bb\u03c0.) \u03ba\u03b1\u03b9 \u03c4\u03b7\u03bd \u03b1\u03bd\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1.<\/p>\n<div class=\"table-scroll\">\n<table>\n<thead>\n<tr>\n<th>\u03a0\u03bb\u03b1\u03af\u03c3\u03b9\u03bf<\/th>\n<th>Standard-risk<\/th>\n<th>High-risk \/ +1q \/ del17p<\/th>\n<th>\u039c\u03b7-ASCT \u03c0\u03bf\u03c1\u03b5\u03af\u03b1<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u039a\u03cd\u03c1\u03b9\u03b1 \u03b5\u03c0\u03b9\u03bb\u03bf\u03b3\u03ae<\/td>\n<td><strong>Lenalidomide<\/strong> \u03bc\u03bf\u03bd\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1<\/td>\n<td>Lenalidomide \u00b1 PI (\u03c0.\u03c7. <em>ixazomib<\/em> \u03ae <em>bortezomib<\/em> \u03b4\u03b9\u03b1\u03ba\u03b5\u03ba\u03bf\u03bc\u03bc\u03ad\u03bd\u03b1)<\/td>\n<td>\u03a3\u03c5\u03bd\u03ad\u03c7\u03b9\u03c3\u03b7 \u03c3\u03c7\u03ae\u03bc\u03b1\u03c4\u03bf\u03c2 \u03c0\u03c1\u03ce\u03c4\u03b7\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2 \u03bc\u03ad\u03c7\u03c1\u03b9 \u03c0\u03c1\u03cc\u03bf\u03b4\u03bf\/\u03c4\u03bf\u03be\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1 (\u03c0.\u03c7. DRd \u03bc\u03b5 \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 \u03b4\u03cc\u03c3\u03b5\u03c9\u03bd)<\/td>\n<\/tr>\n<tr>\n<td>\u0394\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1<\/td>\n<td>\u03a3\u03c5\u03bd\u03ae\u03b8\u03c9\u03c2 \u00ab\u03bc\u03ad\u03c7\u03c1\u03b9 \u03c0\u03c1\u03cc\u03bf\u03b4\u03bf\u00bb, \u03c0\u03bf\u03bb\u03bb\u03bf\u03af \u03c3\u03c4\u03cc\u03c7\u03bf\u03b9 \u22652\u20133 \u03ad\u03c4\u03b7<\/td>\n<td>\u03a0\u03b9\u03bf \u03b5\u03c0\u03b9\u03b8\u03b5\u03c4\u03b9\u03ba\u03ae\/\u03bc\u03b1\u03ba\u03c1\u03cd\u03c4\u03b5\u03c1\u03b7 \u03c0\u03c1\u03bf\u03c3\u03ad\u03b3\u03b3\u03b9\u03c3\u03b7<\/td>\n<td>\u0395\u03be\u03b1\u03c4\u03bf\u03bc\u03af\u03ba\u03b5\u03c5\u03c3\u03b7 \u03b2\u03ac\u03c3\u03b5\u03b9 frailty\/\u03c0\u03bf\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2 \u03b6\u03c9\u03ae\u03c2<\/td>\n<\/tr>\n<tr>\n<td>MRD-guided;<\/td>\n<td>\u03a0\u03c1\u03bf\u03b1\u03b9\u03c1\u03b5\u03c4\u03b9\u03ba\u03ae, \u03b9\u03b4\u03af\u03c9\u03c2 \u03c3\u03b5 \u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03c4\u03b1\u03bc\u03ad\u03bd\u03b7 MRD(\u2013)<\/td>\n<td>\u03a0\u03c1\u03bf\u03c2 \u03c4\u03bf \u03c0\u03b1\u03c1\u03cc\u03bd \u03b5\u03ba\u03c4\u03cc\u03c2 \u03c1\u03bf\u03c5\u03c4\u03af\u03bd\u03b1\u03c2\u00b7 \u03c0\u03c1\u03bf\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03b7 \u03b5\u03bd\u03af\u03c3\u03c7\u03c5\u03c3\u03b7<\/td>\n<td>\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h3>9.1 \u03a0\u03c1\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2 \u03a3\u03c5\u03bc\u03b2\u03bf\u03c5\u03bb\u03ad\u03c2<\/h3>\n<ul>\n<li><strong>\u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 Len<\/strong>: \u03ad\u03bd\u03b1\u03c1\u03be\u03b7 10 mg qd \u2192 \u03c4\u03b9\u03c4\u03bb\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 15 mg \u03cc\u03c0\u03bf\u03c5 \u03b1\u03bd\u03b5\u03ba\u03c4\u03cc\u00b7 \u03c0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ad\u03c2 \u03c3\u03b5 eGFR\/\u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03bf\u03c0\u03b5\u03bd\u03af\u03b1.<\/li>\n<li><strong>\u0398\u03c1\u03cc\u03bc\u03b2\u03c9\u03c3\u03b7<\/strong> \u03bc\u03b5 IMiDs: \u03b4\u03b5\u03c2 \u00a712.4 \u03b3\u03b9\u03b1 \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7 (ASA\/LMWH\/DOAC \u03b1\u03bd\u03ac \u03c1\u03af\u03c3\u03ba\u03bf).<\/li>\n<li><strong>\u0394\u03b5\u03cd\u03c4\u03b5\u03c1\u03b5\u03c2 \u03ba\u03b1\u03ba\u03bf\u03ae\u03b8\u03b5\u03b9\u03b5\u03c2<\/strong>: \u03bc\u03b9\u03ba\u03c1\u03cc\u03c2 \u03b1\u03c5\u03be\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2\u00b7 \u03c4\u03bf \u03cc\u03c6\u03b5\u03bb\u03bf\u03c2 PFS\/OS \u03c3\u03c5\u03bd\u03ae\u03b8\u03c9\u03c2 \u03c5\u03c0\u03b5\u03c1\u03b9\u03c3\u03c7\u03cd\u03b5\u03b9.<\/li>\n<li><strong>\u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7<\/strong>: CBC\/\u03c7\u03b7\u03bc\u03b5\u03af\u03b1\/\u03b8\u03c5\u03c1\u03b5\u03bf\u03b5\u03b9\u03b4\u03ae\u03c2, SPEP\/FLC \u03b1\u03bd\u03ac 1\u20133 \u03bc\u03ae\u03bd\u03b5\u03c2 \u03b1\u03c1\u03c7\u03b9\u03ba\u03ac.<\/li>\n<\/ul>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= SECTION 10 ========================= --><\/p>\n<h2 id=\"sec-10\" class=\"anchor\">10) \u03a5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03ae\/\u0391\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u039d\u03cc\u03c3\u03bf\u03c2 (RRMM)<\/h2>\n<div class=\"infobox success\">\n<h4>\u03a3\u03c4\u03c1\u03b1\u03c4\u03b7\u03b3\u03b9\u03ba\u03ae \u03b5\u03c0\u03b9\u03bb\u03bf\u03b3\u03ae\u03c2 \u03c3\u03c7\u03ae\u03bc\u03b1\u03c4\u03bf\u03c2<\/h4>\n<ul>\n<li><strong>\u03a4\u03b9 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc;<\/strong> \u03a0.\u03c7. \u00ablen-refractory\u00bb = \u03c0\u03c1\u03cc\u03bf\u03b4\u03bf\u03c2 \u03b5\u03bd\u03cc\u03c3\u03c9 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03b9 \u03ae \u226460 \u03b7\u03bc\u03ad\u03c1\u03b5\u03c2 \u03b1\u03c0\u03cc \u03b4\u03b9\u03b1\u03ba\u03bf\u03c0\u03ae lenalidomide.<\/li>\n<li><strong>\u03a0\u03cc\u03c4\u03b5 \u03b1\u03bd\u03c4\u03b9-CD38;<\/strong> \u0391\u03bd \u03b4\u03b5\u03bd \u03ad\u03c7\u03b5\u03b9 \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b7\u03b8\u03b5\u03af\/\u03b5\u03be\u03b1\u03bd\u03c4\u03bb\u03b7\u03b8\u03b5\u03af, <em>daratumumab<\/em> \u03ae <em>isatuximab<\/em> \u03b5\u03af\u03bd\u03b1\u03b9 \u03bc\u03bf\u03c7\u03bb\u03bf\u03af \u03b1\u03c0\u03bf\u03c4\u03b5\u03bb\u03b5\u03c3\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2.<\/li>\n<li><strong>\u03a0\u03cc\u03c4\u03b5 carfilzomib;<\/strong> \u03a7\u03c1\u03ae\u03c3\u03b9\u03bc\u03bf \u03c3\u03b5 \u03c0\u03c1\u03ce\u03b9\u03bc\u03b7 \u03c5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03ae\/\u03c5\u03c8\u03b7\u03bb\u03cc \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf, \u03b9\u03b4\u03af\u03c9\u03c2 \u03bc\u03b5\u03c4\u03ac \u03b1\u03c0\u03cc bortezomib.<\/li>\n<\/ul>\n<\/div>\n<h3>10.1 \u0391\u03c0\u03bb\u03cc\u03c2 \u0391\u03bb\u03b3\u03cc\u03c1\u03b9\u03b8\u03bc\u03bf\u03c2 (\u03c0\u03c1\u03ce\u03c4\u03b7\u2013\u03b4\u03b5\u03cd\u03c4\u03b5\u03c1\u03b7 \u03c5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03ae)<\/h3>\n<div class=\"table-scroll\">\n<table>\n<thead>\n<tr>\n<th>\u039a\u03b1\u03c4\u03ac\u03c3\u03c4\u03b1\u03c3\u03b7<\/th>\n<th>\u03a0\u03c1\u03bf\u03c4\u03b5\u03b9\u03bd\u03cc\u03bc\u03b5\u03bd\u03b1 \u03c4\u03c1\u03af\u03c0\u03bb\u03b5\u03c4\/\u03c4\u03b5\u03c4\u03c1\u03ac\u03c0\u03bb\u03b5\u03c4<\/th>\n<th>\u03a3\u03c7\u03cc\u03bb\u03b9\u03b1<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Len-refractory<\/td>\n<td><strong>DKd<\/strong> (dara+carfilzomib+dex), <strong>IsaKd<\/strong>, <strong>DPd<\/strong> (dara+pomalidomide+dex), <strong>IsaPd<\/strong><\/td>\n<td>\u0399\u03c3\u03c7\u03c5\u03c1\u03ae \u03b1\u03bd\u03c4\u03b9\u03bd\u03cc\u03c3\u03bf\u03c2 \u03b4\u03c1\u03ac\u03c3\u03b7\u00b7 \u03c0\u03c1\u03bf\u03c3\u03bf\u03c7\u03ae \u03c3\u03b5 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03ac \u03bc\u03b5 Kd<\/td>\n<\/tr>\n<tr>\n<td>PI-refractory<\/td>\n<td><strong>DRd<\/strong>, <strong>KRd<\/strong>, <strong>EPd<\/strong> (elotuzumab+pomalidomide+dex)<\/td>\n<td>\u0391\u03bd \u03b4\u03b5\u03bd \u03ad\u03c7\u03b5\u03b9 \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b7\u03b8\u03b5\u03af anti-CD38, \u03b1\u03be\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03ad \u03c4\u03bf<\/td>\n<\/tr>\n<tr>\n<td>\u0391\u03bc\u03c6\u03cc\u03c4\u03b5\u03c1\u03b1 \u03b5\u03ba\u03c4\u03b5\u03b8\u03b5\u03b9\u03bc\u03ad\u03bd\u03b1 (IMiD+PI)<\/td>\n<td><strong>Selinexor-based<\/strong> (\u03c0.\u03c7. XVd), <strong>Alkylator-based<\/strong> (\u03ba\u03c5\u03ba\u03bb\u03bf\u03c6\u03c9\u03c3\u03c6\u03b1\u03bc\u03af\u03b4\u03b7), <strong>Belantamab<\/strong> (\u03ba\u03b1\u03c4\u03ac \u03ad\u03bd\u03b4\u03b5\u03b9\u03be\u03b7)<\/td>\n<td>\u03a3\u03ba\u03ad\u03c8\u03bf\u03c5 \u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u03b4\u03bf\u03ba\u03b9\u03bc\u03ae \u03ae \u00ab\u03b3\u03ad\u03c6\u03c5\u03c1\u03b1\u00bb \u03c0\u03c1\u03bf\u03c2 \u00a711<\/td>\n<\/tr>\n<tr>\n<td>\u039c\u03b5\u03b3\u03ac\u03bb\u03bf TFI \u03bc\u03b5\u03c4\u03ac ASCT (&gt;18\u201324 \u03bc.)<\/td>\n<td><strong>Salvage ASCT<\/strong> \u03c3\u03b5 \u03b5\u03c0\u03b9\u03bb\u03b5\u03b3\u03bc\u03ad\u03bd\u03bf\u03c5\u03c2<\/td>\n<td>\u03a3\u03c5\u03b6\u03b7\u03c4\u03b5\u03af\u03c4\u03b1\u03b9 \u03c3\u03b5 \u03ba\u03ad\u03bd\u03c4\u03c1\u03b1 \u03bc\u03b5 \u03b5\u03bc\u03c0\u03b5\u03b9\u03c1\u03af\u03b1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h3>10.2 \u03a4\u03cd\u03c0\u03bf\u03c2 \u03a5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03ae\u03c2 &amp; \u03a1\u03c5\u03b8\u03bc\u03cc\u03c2<\/h3>\n<ul>\n<li><strong>\u0392\u03b9\u03bf\u03c7\u03b7\u03bc\u03b9\u03ba\u03ae<\/strong> (\u03bc\u03cc\u03bd\u03bf \u03b1\u03cd\u03be\u03b7\u03c3\u03b7 M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2\/FLC): \u03c3\u03c5\u03c7\u03bd\u03ae \u03b5\u03c0\u03b1\u03bd\u03b5\u03ba\u03c4\u03af\u03bc\u03b7\u03c3\u03b7, \u03ad\u03bd\u03b1\u03c1\u03be\u03b7 \u03cc\u03c4\u03b1\u03bd \u03c0\u03bb\u03b7\u03c1\u03bf\u03af IMWG \u00abprogression\u00bb \u03ae \u03b1\u03bd \u03c5\u03c8\u03b7\u03bb\u03bf\u03cd \u03ba\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5.<\/li>\n<li><strong>\u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae<\/strong> (\u03bd\u03ad\u03b1 CRAB\/\u03c0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03cd\u03c4\u03c4\u03c9\u03bc\u03b1): \u03ac\u03bc\u03b5\u03c3\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1, \u03c0\u03c1\u03bf\u03c4\u03af\u03bc\u03b7\u03c3\u03b7 \u03c3\u03b5 \u03c4\u03b1\u03c7\u03b5\u03af\u03b1\/\u03b2\u03b1\u03b8\u03b9\u03ac \u03b1\u03c0\u03bf\u03ba\u03c1\u03af\u03c3\u03b7.<\/li>\n<\/ul>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= SECTION 11 ========================= --><\/p>\n<h2 id=\"sec-11\" class=\"anchor\">11) \u039d\u03b5\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b5\u03c2: CAR-T &amp; \u0394\u03b9\u03b5\u03b9\u03b4\u03b9\u03ba\u03ac \u0391\u03bd\u03c4\u03b9\u03c3\u03ce\u03bc\u03b1\u03c4\u03b1<\/h2>\n<p class=\"lead\">\u039f\u03b9 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b5\u03c2 \u03c0\u03bf\u03c5 \u03c3\u03c4\u03bf\u03c7\u03b5\u03cd\u03bf\u03c5\u03bd \u03c4\u03bf <strong>BCMA<\/strong> (\u03ba\u03b1\u03b9 \u03bd\u03b5\u03cc\u03c4\u03b5\u03c1\u03b1 \u03c4\u03bf\u03bd <strong>GPRC5D<\/strong>) \u03ad\u03c7\u03bf\u03c5\u03bd \u03b1\u03bb\u03bb\u03ac\u03be\u03b5\u03b9 \u03c4\u03bf \u03c4\u03bf\u03c0\u03af\u03bf \u03c3\u03c4\u03b7\u03bd \u03c0\u03bf\u03bb\u03c5\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03bc\u03ad\u03bd\u03b7 \u03bd\u03cc\u03c3\u03bf, \u03c0\u03c1\u03bf\u03c3\u03c6\u03ad\u03c1\u03bf\u03bd\u03c4\u03b1\u03c2 \u03b2\u03b1\u03b8\u03b9\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03c4\u03b1\u03bc\u03ad\u03bd\u03b5\u03c2 \u03b1\u03c0\u03bf\u03ba\u03c1\u03af\u03c3\u03b5\u03b9\u03c2.<\/p>\n<h3>11.1 CAR-T (BCMA)<\/h3>\n<ul>\n<li><strong>\u0394\u03b9\u03b1\u03b4\u03b9\u03ba\u03b1\u03c3\u03af\u03b1<\/strong>: \u03bb\u03b5\u03c5\u03ba\u03b1\u03c6\u03b1\u03af\u03c1\u03b5\u03c3\u03b7 \u2192 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03ae \u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd (ex vivo) \u2192 <em>lymphodepletion<\/em> (\u03c3\u03c5\u03bd\u03ae\u03b8\u03c9\u03c2 Flu\/Cy) \u2192 \u03ad\u03b3\u03c7\u03c5\u03c3\u03b7 \u2192 \u03c3\u03c4\u03b5\u03bd\u03ae \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7.<\/li>\n<li><strong>\u03a0\u03bb\u03b5\u03bf\u03bd\u03b5\u03ba\u03c4\u03ae\u03bc\u03b1\u03c4\u03b1<\/strong>: \u03bc\u03bf\u03bd\u03bf\u03b4\u03bf\u03c3\u03b9\u03ba\u03ae \u03c0\u03c1\u03bf\u03c3\u03ad\u03b3\u03b3\u03b9\u03c3\u03b7, \u03c5\u03c8\u03b7\u03bb\u03ac \u03c0\u03bf\u03c3\u03bf\u03c3\u03c4\u03ac CR\/MRD(\u2013) \u03c3\u03b5 \u03b1\u03bd\u03b8\u03b5\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c3\u03b5\u03b9\u03c1\u03ad\u03c2.<\/li>\n<li><strong>\u03a0\u03c1\u03bf\u03ba\u03bb\u03ae\u03c3\u03b5\u03b9\u03c2<\/strong>: \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03ae\u03c2, \u03b1\u03bd\u03ac\u03b3\u03ba\u03b7 \u00abbridging therapy\u00bb, \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03b9 <em>CRS<\/em> &amp; <em>ICANS<\/em>, \u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03bf\u03c0\u03b5\u03bd\u03af\u03b5\u03c2\/\u03bb\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2.<\/li>\n<\/ul>\n<div class=\"infobox neutral\">\n<h4>CRS &amp; ICANS (\u03b2\u03b1\u03c3\u03b9\u03ba\u03ac)<\/h4>\n<ul>\n<li><strong>CRS<\/strong>: \u03c0\u03c5\u03c1\u03b5\u03c4\u03cc\u03c2, \u03c5\u03c0\u03cc\u03c4\u03b1\u03c3\u03b7, \u03c5\u03c0\u03bf\u03be\u03c5\u03b3\u03bf\u03bd\u03b1\u03b9\u03bc\u03af\u03b1. \u0391\u03bd\u03c4\u03b9\u03bc\u03b5\u03c4\u03ce\u03c0\u03b9\u03c3\u03b7: \u03c5\u03c0\u03bf\u03c3\u03c4\u03ae\u03c1\u03b9\u03be\u03b7, <em>tocilizumab<\/em> \u00b1 \u03ba\u03bf\u03c1\u03c4\u03b9\u03ba\u03bf\u03c3\u03c4\u03b5\u03c1\u03bf\u03b5\u03b9\u03b4\u03ae \u03b1\u03bd\u03ac \u03b2\u03b1\u03b8\u03bc\u03cc.<\/li>\n<li><strong>ICANS<\/strong>: \u03bd\u03b5\u03c5\u03c1\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ad\u03c2 \u03b5\u03ba\u03b4\u03b7\u03bb\u03ce\u03c3\u03b5\u03b9\u03c2 (\u03c3\u03cd\u03b3\u03c7\u03c5\u03c3\u03b7, \u03b4\u03c5\u03c3\u03c6\u03b1\u03c3\u03af\u03b1, \u03c3\u03c0\u03b1\u03c3\u03bc\u03bf\u03af). \u0391\u03bd\u03c4\u03b9\u03bc\u03b5\u03c4\u03ce\u03c0\u03b9\u03c3\u03b7: \u03ba\u03bf\u03c1\u03c4\u03b9\u03ba\u03bf\u03c3\u03c4\u03b5\u03c1\u03bf\u03b5\u03b9\u03b4\u03ae, \u03b1\u03bd\u03c4\u03b9\u03b5\u03c0\u03b9\u03bb\u03b7\u03c0\u03c4\u03b9\u03ba\u03ae \u03ba\u03ac\u03bb\u03c5\u03c8\u03b7.<\/li>\n<\/ul>\n<\/div>\n<h3>11.2 \u0394\u03b9\u03b5\u03b9\u03b4\u03b9\u03ba\u03ac \u0391\u03bd\u03c4\u03b9\u03c3\u03ce\u03bc\u03b1\u03c4\u03b1 (BsAbs)<\/h3>\n<ul>\n<li><strong>BCMA-BsAbs<\/strong> (\u03c0.\u03c7. \u03c4\u03b5\u03ba\u03bb\u03b9\u03c3\u03c4\u03b1\u03bc\u03ac\u03bc\u03c0\u03b7, \u03b5\u03bb\u03c1\u03b1\u03bd\u03b1\u03c4\u03b1\u03bc\u03ac\u03bc\u03c0\u03b7): \u03c3\u03c5\u03bd\u03b5\u03c7\u03cc\u03bc\u03b5\u03bd\u03b7 \u03c7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7 \u03bc\u03b5 <em>step-up<\/em> \u03b4\u03cc\u03c3\u03b5\u03b9\u03c2\u00b7 \u03c5\u03c8\u03b7\u03bb\u03ad\u03c2 \u03b1\u03bd\u03c4\u03b1\u03c0\u03bf\u03ba\u03c1\u03af\u03c3\u03b5\u03b9\u03c2.<\/li>\n<li><strong>GPRC5D-BsAbs<\/strong> (\u03c0.\u03c7. \u03c4\u03b1\u03bb\u03ba\u03b5\u03c4\u03bf\u03c5\u03b6\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7): \u03b1\u03c0\u03bf\u03c4\u03b5\u03bb\u03b5\u03c3\u03bc\u03b1\u03c4\u03b9\u03ba\u03ac \u03b1\u03ba\u03cc\u03bc\u03b7 \u03ba\u03b1\u03b9 \u03bc\u03b5\u03c4\u03ac BCMA-\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b5\u03c2\u00b7 \u03c7\u03b1\u03c1\u03b1\u03ba\u03c4\u03b7\u03c1\u03b9\u03c3\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c4\u03bf\u03be\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b5\u03c2 (\u03b4\u03ad\u03c1\u03bc\u03b1\/\u03c3\u03c4\u03bf\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03ba\u03bf\u03b9\u03bb\u03cc\u03c4\u03b7\u03c4\u03b1\/\u03bd\u03cd\u03c7\u03b9\u03b1\/\u03b3\u03b5\u03cd\u03c3\u03b7).<\/li>\n<li><strong>\u039a\u03bf\u03b9\u03bd\u03cc<\/strong>: \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2 \u03bb\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03c9\u03bd &amp; \u03c5\u03c0\u03bf\u03b3\u03b1\u03bc\u03bc\u03b1\u03c3\u03c6\u03b1\u03b9\u03c1\u03b9\u03bd\u03b1\u03b9\u03bc\u03af\u03b1\u03c2 \u2192 IVIG\/\u03c0\u03c1\u03bf\u03c6\u03c5\u03bb\u03ac\u03be\u03b5\u03b9\u03c2 (\u03b2\u03bb. \u00a712.3).<\/li>\n<\/ul>\n<div class=\"table-scroll\">\n<table>\n<thead>\n<tr>\n<th>\u039a\u03b1\u03c4\u03b7\u03b3\u03bf\u03c1\u03af\u03b1<\/th>\n<th>\u03a3\u03c4\u03cc\u03c7\u03bf\u03c2<\/th>\n<th>\u03a4\u03c1\u03cc\u03c0\u03bf\u03c2<\/th>\n<th>\u039a\u03cd\u03c1\u03b9\u03b1 \u03b6\u03b7\u03c4\u03ae\u03bc\u03b1\u03c4\u03b1<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>CAR-T<\/td>\n<td>BCMA<\/td>\n<td>\u0395\u03c6\u03ac\u03c0\u03b1\u03be \u03ad\u03b3\u03c7\u03c5\u03c3\u03b7 \u03bc\u03b5\u03c4\u03ac \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03ae<\/td>\n<td>CRS\/ICANS, \u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03bf\u03c0\u03b5\u03bd\u03af\u03b5\u03c2, \u03b1\u03bd\u03ac\u03b3\u03ba\u03b7 \u03ba\u03ad\u03bd\u03c4\u03c1\u03bf\u03c5 \u03bc\u03b5 \u03b5\u03bc\u03c0\u03b5\u03b9\u03c1\u03af\u03b1<\/td>\n<\/tr>\n<tr>\n<td>BsAbs<\/td>\n<td>BCMA \/ GPRC5D<\/td>\n<td>\u03a3\u03c5\u03bd\u03b5\u03c7\u03cc\u03bc\u03b5\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 (step-up \u2192 \u03c3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7)<\/td>\n<td>\u039b\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2\/\u03c5\u03c0\u03bf\u03b3\u03b1\u03bc\u03bc\u03b1\u03c3\u03c6\u03b1\u03b9\u03c1\u03b9\u03bd\u03b1\u03b9\u03bc\u03af\u03b1, compliance \u03c3\u03b5 \u03c3\u03c5\u03c7\u03bd\u03ad\u03c2 \u03c7\u03bf\u03c1\u03b7\u03b3\u03ae\u03c3\u03b5\u03b9\u03c2<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= SECTION 12 ========================= --><\/p>\n<h2 id=\"sec-12\" class=\"anchor\">12) \u03a5\u03c0\u03bf\u03c3\u03c4\u03b7\u03c1\u03b9\u03ba\u03c4\u03b9\u03ba\u03ae \u03a6\u03c1\u03bf\u03bd\u03c4\u03af\u03b4\u03b1 &amp; \u03a0\u03c1\u03cc\u03bb\u03b7\u03c8\u03b7 \u0395\u03c0\u03b9\u03c0\u03bb\u03bf\u03ba\u03ce\u03bd<\/h2>\n<h3>12.1 \u039f\u03c3\u03c4\u03b9\u03ba\u03ae \u039d\u03cc\u03c3\u03bf\u03c2<\/h3>\n<ul>\n<li><strong>\u0394\u03b9\u03c6\u03c9\u03c3\u03c6\u03bf\u03bd\u03b9\u03ba\u03ac<\/strong> (\u03b6\u03bf\u03bb\u03b5\u03b4\u03c1\u03bf\u03bd\u03b9\u03ba\u03cc\/\u03c0\u03b1\u03bc\u03b9\u03b4\u03c1\u03bf\u03bd\u03b9\u03ba\u03cc) \u03ae <strong>\u03bd\u03c4\u03b5\u03bd\u03bf\u03c3\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7<\/strong>\u00b7 \u03b1\u03be\u03b9\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7 \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae\u03c2 \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1\u03c2 \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03ba\u03ac\u03b8\u03b5 \u03ba\u03cd\u03ba\u03bb\u03bf.<\/li>\n<li><strong>MRONJ<\/strong> \u03c0\u03c1\u03cc\u03bb\u03b7\u03c8\u03b7: \u03bf\u03b4\u03bf\u03bd\u03c4\u03b9\u03b1\u03c4\u03c1\u03b9\u03ba\u03cc\u03c2 \u03ad\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2 \u03c0\u03c1\u03b9\u03bd \u03c4\u03b7\u03bd \u03ad\u03bd\u03b1\u03c1\u03be\u03b7, \u03c3\u03c4\u03bf\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03b3\u03b9\u03b5\u03b9\u03bd\u03ae, \u03b1\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u03c4\u03c1\u03b1\u03c5\u03bc\u03b1\u03c4\u03b9\u03ba\u03ce\u03bd \u03c0\u03c1\u03ac\u03be\u03b5\u03c9\u03bd \u03cc\u03c0\u03bf\u03c5 \u03b5\u03c6\u03b9\u03ba\u03c4\u03cc.<\/li>\n<li><strong>\u03a3\u03c5\u03bc\u03c0\u03c4\u03ce\u03bc\u03b1\u03c4\u03b1\/\u039a\u03ac\u03c4\u03b1\u03b3\u03bc\u03b1<\/strong>: \u03b1\u03bd\u03b1\u03bb\u03b3\u03b7\u03c3\u03af\u03b1, \u03bf\u03c1\u03b8\u03bf\u03c0\u03b1\u03b9\u03b4\u03b9\u03ba\u03ae \u03b5\u03ba\u03c4\u03af\u03bc\u03b7\u03c3\u03b7, \u03b1\u03ba\u03c4\u03b9\u03bd\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1, \u03ba\u03c5\u03c6\u03bf\u03c0\u03bb\u03b1\u03c3\u03c4\u03b9\u03ba\u03ae\/\u03c3\u03c0\u03bf\u03bd\u03b4\u03c5\u03bb\u03bf\u03c0\u03bb\u03b1\u03c3\u03c4\u03b9\u03ba\u03ae \u03ba\u03b1\u03c4\u03ac \u03ad\u03bd\u03b4\u03b5\u03b9\u03be\u03b7.<\/li>\n<li>\u03a3\u03c5\u03bc\u03c0\u03bb\u03b7\u03c1\u03ce\u03bc\u03b1\u03c4\u03b1 <strong>\u03b1\u03c3\u03b2\u03b5\u03c3\u03c4\u03af\u03bf\u03c5\/\u03b2\u03b9\u03c4\u03b1\u03bc\u03af\u03bd\u03b7\u03c2 D<\/strong> \u03cc\u03c4\u03b1\u03bd \u03b5\u03bd\u03b4\u03b5\u03af\u03ba\u03bd\u03c5\u03bd\u03c4\u03b1\u03b9 (\u03b9\u03b4\u03af\u03c9\u03c2 \u03bc\u03b5 \u03bd\u03c4\u03b5\u03bd\u03bf\u03c3\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7).<\/li>\n<\/ul>\n<h3>12.2 \u039d\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03a0\u03c1\u03bf\u03c3\u03c4\u03b1\u03c3\u03af\u03b1<\/h3>\n<ul>\n<li>\u0395\u03bd\u03c5\u03b4\u03ac\u03c4\u03c9\u03c3\u03b7, \u03b1\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u039c\u03a3\u0391\u03a6\/\u03c3\u03ba\u03b9\u03b1\u03b3\u03c1\u03b1\u03c6\u03b9\u03ba\u03ce\u03bd \u03cc\u03c0\u03bf\u03c5 \u03b3\u03af\u03bd\u03b5\u03c4\u03b1\u03b9\u00b7 \u03c3\u03c4\u03b5\u03bd\u03ae \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7 eGFR\/\u03b7\u03bb\u03b5\u03ba\u03c4\u03c1\u03bf\u03bb\u03c5\u03c4\u03ce\u03bd.<\/li>\n<li><em>Bortezomib-based<\/em> \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c9\u03c2 \u03c1\u03b1\u03c7\u03bf\u03ba\u03bf\u03ba\u03b1\u03bb\u03b9\u03ac \u03c3\u03b5 cast nephropathy\u00b7 \u03c4\u03b1\u03c7\u03b5\u03af\u03b1 \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 FLC.<\/li>\n<li>\u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ad\u03c2 \u03c0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ad\u03c2 IMiDs\/\u03b1\u03bd\u03c4\u03b9\u03bc\u03b9\u03ba\u03c1\u03bf\u03b2\u03b9\u03b1\u03ba\u03ce\u03bd.<\/li>\n<\/ul>\n<h3>12.3 \u03a0\u03c1\u03cc\u03bb\u03b7\u03c8\u03b7 \u039b\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03c9\u03bd &amp; \u0395\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03bf\u03af<\/h3>\n<ul>\n<li><strong>\u0391\u03bd\u03c4\u03b9-\u03b9\u03b9\u03ba\u03ae \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7<\/strong> (HSV\/VZV) \u03c3\u03b5 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b5\u03c2 \u03bc\u03b5 PI\/anti-CD38\/BsAbs\/CAR-T.<\/li>\n<li><strong>PJP \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7<\/strong> \u03c3\u03b5 \u03c5\u03c8\u03b7\u03bb\u03bf\u03cd \u03ba\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5 \u03c3\u03c7\u03ae\u03bc\u03b1\u03c4\u03b1\/\u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03c4\u03b1\u03bc\u03ad\u03bd\u03b1 \u03ba\u03bf\u03c1\u03c4\u03b9\u03ba\u03bf\u03c3\u03c4\u03b5\u03c1\u03bf\u03b5\u03b9\u03b4\u03ae.<\/li>\n<li><strong>IVIG<\/strong> \u03c3\u03b5 \u03c5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03b9\u03ac\u03b6\u03bf\u03c5\u03c3\u03b5\u03c2 \u03bb\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2\/\u03c5\u03c0\u03bf\u03b3\u03b1\u03bc\u03bc\u03b1\u03c3\u03c6\u03b1\u03b9\u03c1\u03b9\u03bd\u03b1\u03b9\u03bc\u03af\u03b1.<\/li>\n<li><strong>\u0395\u03bc\u03b2\u03cc\u03bb\u03b9\u03b1<\/strong>: \u03b5\u03c4\u03ae\u03c3\u03b9\u03b1 \u03b3\u03c1\u03af\u03c0\u03b7, \u03c0\u03bd\u03b5\u03c5\u03bc\u03bf\u03bd\u03b9\u03cc\u03ba\u03bf\u03ba\u03ba\u03bf\u03c2 (\u03c3\u03b5\u03b9\u03c1\u03ac), \u03b1\u03bd\u03b1\u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03ad\u03bd\u03bf \u03b6\u03c9\u03c3\u03c4\u03ae\u03c1\u03b1, \u03b5\u03c0\u03b9\u03ba\u03b1\u03b9\u03c1\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03b1 COVID\u00b7 \u03b1\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u03b6\u03ce\u03bd\u03c4\u03c9\u03bd \u03b5\u03bc\u03b2\u03bf\u03bb\u03af\u03c9\u03bd \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1.<\/li>\n<\/ul>\n<h3>12.4 \u0398\u03c1\u03bf\u03bc\u03b2\u03bf\u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7 \u03bc\u03b5 IMiDs<\/h3>\n<div class=\"table-scroll\">\n<table>\n<thead>\n<tr>\n<th>\u039a\u03b1\u03c4\u03b7\u03b3\u03bf\u03c1\u03af\u03b1 \u03ba\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5<\/th>\n<th>\u03a0\u03b1\u03c1\u03ac\u03b4\u03b5\u03b9\u03b3\u03bc\u03b1 \u03b1\u03c3\u03b8\u03b5\u03bd\u03ce\u03bd<\/th>\n<th>\u03a0\u03c1\u03cc\u03c4\u03b1\u03c3\u03b7<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u03a7\u03b1\u03bc\u03b7\u03bb\u03ae<\/td>\n<td>\u03a7\u03c9\u03c1\u03af\u03c2 \u03bc\u03b5\u03af\u03b6\u03bf\u03bd\u03b5\u03c2 \u03c0\u03b1\u03c1\u03ac\u03b3\u03bf\u03bd\u03c4\u03b5\u03c2 VTE<\/td>\n<td>ASA 81\u2013100 mg\/\u03b7\u03bc.<\/td>\n<\/tr>\n<tr>\n<td>\u0395\u03bd\u03b4\u03b9\u03ac\u03bc\u03b5\u03c3\u03b7<\/td>\n<td>\u22651 \u03c0\u03b1\u03c1\u03ac\u03b3\u03bf\u03bd\u03c4\u03b1\u03c2 (\u03c0\u03b1\u03c7\u03c5\u03c3\u03b1\u03c1\u03ba\u03af\u03b1, \u03b7\u03bb\u03b9\u03ba\u03af\u03b1, \u03c0\u03b5\u03c1\u03b9\u03bf\u03c1\u03b9\u03c3\u03bc\u03ad\u03bd\u03b7 \u03ba\u03b9\u03bd\u03b7\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1)<\/td>\n<td>LMWH \u03c0\u03c1\u03bf\u03c6\u03c5\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ae <em>\u03ae<\/em> DOAC \u03c7\u03b1\u03bc\u03b7\u03bb\u03ae \u03b4\u03cc\u03c3\u03b7<\/td>\n<\/tr>\n<tr>\n<td>\u03a5\u03c8\u03b7\u03bb\u03ae<\/td>\n<td>\u0399\u03c3\u03c4\u03bf\u03c1\u03b9\u03ba\u03cc VTE, \u03b5\u03bd\u03b5\u03c1\u03b3\u03cc\u03c2 \u03ba\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03c2 \u03bc\u03b5 \u03c5\u03c8\u03b7\u03bb\u03cc \u03c6\u03bf\u03c1\u03c4\u03af\u03bf, \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03bf\u03af \u03bc\u03b5 \u03c5\u03c8\u03b7\u03bb\u03ad\u03c2 \u03b4\u03cc\u03c3\u03b5\u03b9\u03c2 \u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7\u03c2<\/td>\n<td>LMWH\/DOAC \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae-\u03c0\u03bb\u03b7\u03c3\u03af\u03bf\u03bd \u03b4\u03cc\u03c3\u03b7, \u03b5\u03be\u03b1\u03c4\u03bf\u03bc\u03af\u03ba\u03b5\u03c5\u03c3\u03b7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h3>12.5 \u03a0\u03b5\u03c1\u03b9\u03c6\u03b5\u03c1\u03b9\u03ba\u03ae \u039d\u03b5\u03c5\u03c1\u03bf\u03c0\u03ac\u03b8\u03b5\u03b9\u03b1 (PN)<\/h3>\n<ul>\n<li><strong>Bortezomib<\/strong>: \u03c0\u03c1\u03bf\u03c4\u03af\u03bc\u03b7\u03c3\u03b7 <em>\u03c5\u03c0\u03bf\u03b4\u03cc\u03c1\u03b9\u03b1\u03c2<\/em> \u03b5\u03b2\u03b4\u03bf\u03bc\u03b1\u03b4\u03b9\u03b1\u03af\u03b1\u03c2 \u03c7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2 \u03b3\u03b9\u03b1 \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 PN.<\/li>\n<li>\u039a\u03bb\u03b9\u03bc\u03ac\u03ba\u03c9\u03c3\u03b7-\u03b1\u03c0\u03bf\u03ba\u03bb\u03b9\u03bc\u03ac\u03ba\u03c9\u03c3\u03b7 \u03b4\u03cc\u03c3\u03b5\u03c9\u03bd, \u03b4\u03b9\u03b1\u03ba\u03bf\u03c0\u03ad\u03c2\/\u03b1\u03bb\u03bb\u03b1\u03b3\u03ae PI \u03cc\u03c4\u03b1\u03bd PN \u2265 grade 2.<\/li>\n<li>\u03a3\u03c5\u03bc\u03c0\u03c4\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03b1\u03b3\u03c9\u03b3\u03ae: \u03b3\u03ba\u03b1\u03bc\u03c0\u03b1\u03c0\u03b5\u03bd\u03c4\u03af\u03bd\u03b7\/\u03c0\u03c1\u03b5\u03b3\u03ba\u03b1\u03bc\u03c0\u03b1\u03bb\u03af\u03bd\u03b7, \u03c6\u03c5\u03c3\u03b9\u03ba\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1, \u03c0\u03c1\u03bf\u03c3\u03c4\u03b1\u03c3\u03af\u03b1 \u03ac\u03ba\u03c1\u03c9\u03bd.<\/li>\n<\/ul>\n<h3>12.6 \u0386\u03bb\u03bb\u03b1 \u03c0\u03c1\u03b1\u03ba\u03c4\u03b9\u03ba\u03ac<\/h3>\n<ul>\n<li><strong>\u0391\u03bd\u03c4\u03b9\u03c3\u03cd\u03bb\u03bb\u03b7\u03c8\u03b7<\/strong> \u03bc\u03b5 IMiDs (\u03c4\u03b5\u03c1\u03b1\u03c4\u03bf\u03b3\u03cc\u03bd\u03b1): \u03b4\u03b9\u03c0\u03bb\u03ae \u03b1\u03bd\u03c4\u03b9\u03c3\u03cd\u03bb\u03bb\u03b7\u03c8\u03b7, \u03c4\u03b5\u03c3\u03c4 \u03ba\u03cd\u03b7\u03c3\u03b7\u03c2 \u03ba\u03b1\u03c4\u03ac \u03c0\u03c1\u03c9\u03c4\u03cc\u03ba\u03bf\u03bb\u03bb\u03bf.<\/li>\n<li><strong>\u0393\u03b1\u03c3\u03c4\u03c1\u03b5\u03bd\u03c4\u03b5\u03c1\u03b9\u03ba\u03ac<\/strong>: \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7 \u03b4\u03c5\u03c3\u03ba\u03bf\u03b9\u03bb\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2 \u03bc\u03b5 \u03bf\u03c0\u03b9\u03bf\u03b5\u03b9\u03b4\u03ae\/\u03b8\u03b1\u03bb\u03b9\u03b4\u03bf\u03bc\u03af\u03b4\u03b7, \u03b4\u03b9\u03b1\u03c7\u03b5\u03af\u03c1\u03b9\u03c3\u03b7 \u03b4\u03b9\u03ac\u03c1\u03c1\u03bf\u03b9\u03b1\u03c2 (\u03c0.\u03c7. \u03bc\u03b5 lenalidomide) \u03bc\u03b5 \u03b4\u03b9\u03b1\u03c4\u03c1\u03bf\u03c6\u03b9\u03ba\u03ad\u03c2 \u03bf\u03b4\u03b7\u03b3\u03af\u03b5\u03c2 &amp; \u03bb\u03bf\u03c0\u03b5\u03c1\u03b1\u03bc\u03af\u03b4\u03b7.<\/li>\n<li><strong>\u0386\u03c3\u03ba\u03b7\u03c3\u03b7\/\u0394\u03b9\u03b1\u03c4\u03c1\u03bf\u03c6\u03ae<\/strong>: \u03b5\u03be\u03b1\u03c4\u03bf\u03bc\u03b9\u03ba\u03b5\u03c5\u03bc\u03ad\u03bd\u03bf \u03c0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03b1\u03bd\u03c4\u03bf\u03c7\u03ae\u03c2-\u03b5\u03bd\u03b4\u03c5\u03bd\u03ac\u03bc\u03c9\u03c3\u03b7\u03c2 (\u03c0\u03c1\u03bf\u03c3\u03c4\u03b1\u03c3\u03af\u03b1 \u03c3\u03ba\u03b5\u03bb\u03b5\u03c4\u03bf\u03cd) \u03ba\u03b1\u03b9 \u03bc\u03b5\u03c3\u03bf\u03b3\u03b5\u03b9\u03b1\u03ba\u03bf\u03cd \u03c4\u03cd\u03c0\u03bf\u03c5 \u03b4\u03b9\u03b1\u03c4\u03c1\u03bf\u03c6\u03ae.<\/li>\n<\/ul>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= \u03a0\u039f\u039b\u039b\u0391\u03a0\u039b\u039f \u039c\u03a5\u0395\u039b\u03a9\u039c\u0391 \u2013 \u039f\u0394\u0397\u0393\u039f\u03a3 (\u039c\u0395\u03a1\u039f\u03a3 \u0393: Sections 13\u201318) Mobile-friendly HTML \u03b3\u03b9\u03b1 Classic Editor ========================= --><\/p>\n<p><!-- \u039c\u03b9\u03ba\u03c1\u03cc \u03c4\u03bf\u03c0\u03b9\u03ba\u03cc TOC (\u03c0\u03c1\u03bf\u03b1\u03b9\u03c1\u03b5\u03c4\u03b9\u03ba\u03cc) --><\/p>\n<div class=\"toc\"><\/div>\n<p><!-- ========================= SECTION 13 ========================= --><\/p>\n<h2 id=\"sec-13\" class=\"anchor\">13) Frailty &amp; \u0395\u03be\u03b1\u03c4\u03bf\u03bc\u03af\u03ba\u03b5\u03c5\u03c3\u03b7 \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<\/h2>\n<div class=\"infobox success\">\n<h4>\u0393\u03b9\u03b1\u03c4\u03af \u03bc\u03b5\u03c4\u03c1\u03ac \u03c4\u03bf frailty;<\/h4>\n<p>\u03a4\u03bf <em>frailty<\/em> \u03c0\u03c1\u03bf\u03b2\u03bb\u03ad\u03c0\u03b5\u03b9 \u03c4\u03bf\u03be\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b5\u03c2, \u03b4\u03b9\u03b1\u03ba\u03bf\u03c0\u03ad\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03ba\u03b1\u03b9 \u03c3\u03c5\u03bd\u03bf\u03bb\u03b9\u03ba\u03ac \u03b1\u03c0\u03bf\u03c4\u03b5\u03bb\u03ad\u03c3\u03bc\u03b1\u03c4\u03b1. \u0397 \u03c0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ae \u03ad\u03bd\u03c4\u03b1\u03c3\u03b7\u03c2 (\u03b9\u03b4\u03af\u03c9\u03c2 \u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7\u03c2) \u03b2\u03b5\u03bb\u03c4\u03b9\u03ce\u03bd\u03b5\u03b9 \u03b1\u03bd\u03b5\u03ba\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1 \u03c7\u03c9\u03c1\u03af\u03c2 \u03bc\u03b5\u03b3\u03ac\u03bb\u03b7 \u03b1\u03c0\u03ce\u03bb\u03b5\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c4\u03b5\u03bb\u03b5\u03c3\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2.<\/p>\n<\/div>\n<h3>13.1 \u0395\u03ba\u03c4\u03af\u03bc\u03b7\u03c3\u03b7 Frailty<\/h3>\n<ul>\n<li><strong>\u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ad\u03c2 \u03ba\u03bb\u03af\u03bc\u03b1\u03ba\u03b5\u03c2<\/strong>: IMWG frailty score, R-MCI (Revised Myeloma Comorbidity Index), ADL\/IADL.<\/li>\n<li><strong>\u0392\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03bf\u03af \u03b4\u03b5\u03af\u03ba\u03c4\u03b5\u03c2<\/strong>: \u03c3\u03b1\u03c1\u03ba\u03bf\u03c0\u03b5\u03bd\u03af\u03b1, \u03b1\u03c0\u03ce\u03bb\u03b5\u03b9\u03b1 \u03b2\u03ac\u03c1\u03bf\u03c5\u03c2, \u03b1\u03bb\u03b2\u03bf\u03c5\u03bc\u03af\u03bd\u03b7, \u03c6\u03bb\u03b5\u03b3\u03bc\u03bf\u03bd\u03ce\u03b4\u03b5\u03b9\u03c2 \u03b4\u03b5\u03af\u03ba\u03c4\u03b5\u03c2.<\/li>\n<\/ul>\n<h3>13.2 \u0391\u03c1\u03c7\u03ad\u03c2 Dose-Modification<\/h3>\n<ul>\n<li><strong>\u0394\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7<\/strong>: \u03c3\u03c5\u03c7\u03bd\u03ac \u226420 mg\/\u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b1 \u03c3\u03b5 \u03b7\u03bb\u03b9\u03ba\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf\u03c5\u03c2 \u03ae \u03b5\u03c5\u03b8\u03c1\u03b1\u03cd\u03c3\u03c4\u03bf\u03c5\u03c2 (\u03c0.\u03c7. \u00abVRd-lite\u00bb \u03ae \u00abDRd \u03bc\u03b5 \u03c7\u03b1\u03bc\u03b7\u03bb\u03ae dex\u00bb).<\/li>\n<li><strong>IMiDs<\/strong>: \u03ad\u03bd\u03b1\u03c1\u03be\u03b7 \u03c3\u03b5 \u03c7\u03b1\u03bc\u03b7\u03bb\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03b4\u03cc\u03c3\u03b5\u03b9\u03c2 \u03bc\u03b5 \u03c4\u03b9\u03c4\u03bb\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 (\u03b9\u03b4\u03af\u03c9\u03c2 \u03c3\u03b5 eGFR\u2193\/\u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03bf\u03c0\u03b5\u03bd\u03af\u03b1).<\/li>\n<li><strong>PI<\/strong>: \u03b5\u03b2\u03b4\u03bf\u03bc\u03b1\u03b4\u03b9\u03b1\u03af\u03bf <em>bortezomib<\/em> \u03c5\u03c0\u03bf\u03b4\u03cc\u03c1\u03b9\u03b1 \u03b3\u03b9\u03b1 \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 PN\u00b7 <em>carfilzomib<\/em> \u03bc\u03b5 \u03c0\u03c1\u03bf\u03c3\u03bf\u03c7\u03ae \u03c3\u03b5 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03bf\u03cd\u03c2.<\/li>\n<li><strong>Breaks\/stop rules<\/strong>: \u03b1\u03c1\u03c1\u03c5\u03b8\u03bc\u03af\u03b5\u03c2, grade \u22653 \u03bb\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2, \u03c3\u03bf\u03b2\u03b1\u03c1\u03ae PN, \u03bc\u03b7 \u03b1\u03bd\u03c4\u03b9\u03c1\u03c1\u03bf\u03c0\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae\/\u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b5\u03c0\u03b9\u03b4\u03b5\u03af\u03bd\u03c9\u03c3\u03b7.<\/li>\n<\/ul>\n<h3>13.3 \u03a3\u03c4\u03cc\u03c7\u03bf\u03b9 \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 &amp; \u03a3\u03c5\u03b6\u03ae\u03c4\u03b7\u03c3\u03b7 \u03a0\u03c1\u03bf\u03c4\u03b9\u03bc\u03ae\u03c3\u03b5\u03c9\u03bd<\/h3>\n<ul>\n<li>\u03a1\u03b5\u03b1\u03bb\u03b9\u03c3\u03c4\u03b9\u03ba\u03cc\u03c2 \u03c3\u03c4\u03cc\u03c7\u03bf\u03c2: \u03b2\u03b1\u03b8\u03b9\u03ac \u03b1\u03bb\u03bb\u03ac \u03b1\u03bd\u03b5\u03ba\u03c4\u03ae \u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7\u00b7 \u03ad\u03bc\u03c6\u03b1\u03c3\u03b7 \u03c3\u03c4\u03b7\u03bd <em>\u03c0\u03bf\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1 \u03b6\u03c9\u03ae\u03c2<\/em>.<\/li>\n<li>\u039a\u03bf\u03b9\u03bd\u03ae \u03bb\u03ae\u03c8\u03b7 \u03b1\u03c0\u03cc\u03c6\u03b1\u03c3\u03b7\u03c2 (shared decision-making) \u03bc\u03b5 \u03c0\u03b1\u03c1\u03bf\u03c5\u03c3\u03af\u03b1\u03c3\u03b7 \u03b5\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ce\u03bd (\u03c0.\u03c7. DRd vs VRd-lite).<\/li>\n<\/ul>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= SECTION 14 ========================= --><\/p>\n<h2 id=\"sec-14\" class=\"anchor\">14) \u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7, \u0391\u03be\u03b9\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7 \u0391\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7\u03c2 &amp; MRD<\/h2>\n<h3>14.1 \u03a0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7\u03c2<\/h3>\n<ul>\n<li><strong>\u0395\u03bd\u03b5\u03c1\u03b3\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1<\/strong>: CBC\/\u03c7\u03b7\u03bc\u03b5\u03af\u03b1 \u03ba\u03ac\u03b8\u03b5 \u03ba\u03cd\u03ba\u03bb\u03bf, SPEP\/IFE &amp; FLC \u03b1\u03bd\u03ac 1\u20132 \u03ba\u03cd\u03ba\u03bb\u03bf\u03c5\u03c2.<\/li>\n<li><strong>\u03a3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7<\/strong>: CBC\/\u03c7\u03b7\u03bc\u03b5\u03af\u03b1 \u03ba\u03b1\u03b9 SPEP\/FLC \u03b1\u03bd\u03ac 1\u20133 \u03bc\u03ae\u03bd\u03b5\u03c2, \u03b1\u03bd\u03ac \u03c1\u03af\u03c3\u03ba\u03bf.<\/li>\n<li><strong>\u0391\u03c0\u03b5\u03b9\u03ba\u03cc\u03bd\u03b9\u03c3\u03b7<\/strong>: \u03ba\u03b1\u03c4\u03ac \u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u03ad\u03bd\u03b4\u03b5\u03b9\u03be\u03b7 \u03ae \u03cc\u03c4\u03b1\u03bd \u03c5\u03c0\u03ac\u03c1\u03c7\u03b5\u03b9 \u03b1\u03c3\u03c5\u03bc\u03c6\u03c9\u03bd\u03af\u03b1 \u03b2\u03b9\u03bf\u03c7\u03b7\u03bc\u03b9\u03ba\u03ae\u03c2 \u03b5\u03b9\u03ba\u03cc\u03bd\u03b1\u03c2 (LD-WBCT, PET-CT, WB-MRI).<\/li>\n<\/ul>\n<h3>14.2 \u039a\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 \u0391\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7\u03c2 (IMWG)<\/h3>\n<div class=\"table-scroll\">\n<table>\n<thead>\n<tr>\n<th>\u0392\u03b1\u03b8\u03bc\u03cc\u03c2<\/th>\n<th>\u03a3\u03cd\u03bd\u03bf\u03c8\u03b7<\/th>\n<th>\u03a3\u03c7\u03cc\u03bb\u03b9\u03b1<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Stringent CR (sCR)<\/strong><\/td>\n<td>CR + \u03c6\u03c5\u03c3\u03b9\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae FLC \u03b1\u03bd\u03b1\u03bb\u03bf\u03b3\u03af\u03b1 + \u03b1\u03c1\u03bd\u03b7\u03c4\u03b9\u03ba\u03ae \u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03bf\u03bc\u03b5\u03c4\u03c1\u03af\u03b1 (\u03ba\u03bb\u03c9\u03bd\u03b9\u03ba\u03ac PC)<\/td>\n<td>\u03a3\u03c5\u03bd\u03b4\u03ad\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b5 \u03ba\u03b1\u03bb\u03cd\u03c4\u03b5\u03c1\u03bf PFS\/OS<\/td>\n<\/tr>\n<tr>\n<td><strong>CR<\/strong><\/td>\n<td>\u0391\u03c1\u03bd\u03b7\u03c4\u03b9\u03ba\u03ae IFE \u03bf\u03c1\u03bf\u03cd\/\u03bf\u03cd\u03c1\u03c9\u03bd, \u03b5\u03be\u03b1\u03c6\u03ac\u03bd\u03b9\u03c3\u03b7 \u03c0\u03bb\u03b1\u03c3\u03bc\u03bf\u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03bd<\/td>\n<td>\u2014<\/td>\n<\/tr>\n<tr>\n<td><strong>VGPR<\/strong><\/td>\n<td>\u2193 M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 \u226590% (\u03ae IFE+ \u03bc\u03cc\u03bd\u03bf)<\/td>\n<td>\u039a\u03b1\u03bb\u03cc\u03c2 \u03c3\u03c4\u03cc\u03c7\u03bf\u03c2 \u03b3\u03b9\u03b1 \u03c0\u03bf\u03bb\u03bb\u03bf\u03cd\u03c2 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2<\/td>\n<\/tr>\n<tr>\n<td><strong>PR<\/strong><\/td>\n<td>\u2193 M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 \u226550% (\u03ae \u03b9\u03c3\u03bf\u03b4\u03cd\u03bd\u03b1\u03bc\u03bf \u03c3\u03b5 FLC)<\/td>\n<td>\u2014<\/td>\n<\/tr>\n<tr>\n<td><strong>SD<\/strong><\/td>\n<td>\u039c\u03b7 \u03c0\u03bb\u03ae\u03c1\u03c9\u03c3\u03b7 PR\/PD<\/td>\n<td>\u2014<\/td>\n<\/tr>\n<tr>\n<td><strong>PD<\/strong><\/td>\n<td>\u0391\u03cd\u03be\u03b7\u03c3\u03b7 M-\u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2\/FLC \u03ae \u03bd\u03ad\u03b1 CRAB\/\u03c0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03cd\u03c4\u03c4\u03c9\u03bc\u03b1<\/td>\n<td>\u0388\u03bd\u03b1\u03c1\u03be\u03b7\/\u03b1\u03bb\u03bb\u03b1\u03b3\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h3>14.3 MRD: \u03a4\u03b9 \u03c3\u03b7\u03bc\u03b1\u03af\u03bd\u03b5\u03b9 \u03c3\u03c4\u03b7\u03bd \u03c0\u03c1\u03ac\u03be\u03b7;<\/h3>\n<ul>\n<li><strong>\u03a4\u03b5\u03c7\u03bd\u03b9\u03ba\u03ad\u03c2<\/strong>: <em>NGF<\/em> \u03ae <em>NGS<\/em> \u03bc\u03b5 \u03b5\u03c5\u03b1\u03b9\u03c3\u03b8\u03b7\u03c3\u03af\u03b1 \u226510<sup>\u22125<\/sup> \u03ad\u03c9\u03c2 10<sup>\u22126<\/sup>\u00b7 \u03c3\u03c5\u03bc\u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc <em>imaging-MRD<\/em> \u03bc\u03b5 PET-CT.<\/li>\n<li><strong>MRD-\u03b1\u03c1\u03bd\u03b7\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1<\/strong>: \u03c3\u03c5\u03c3\u03c7\u03b5\u03c4\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b5 \u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03c4\u03b1\u03bc\u03ad\u03bd\u03bf PFS\/OS\u00b7 \u00ab\u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03c4\u03b1\u03bc\u03ad\u03bd\u03b7\u00bb \u03cc\u03c4\u03b1\u03bd \u03c4\u03b5\u03ba\u03bc\u03b7\u03c1\u03b9\u03ce\u03bd\u03b5\u03c4\u03b1\u03b9 \u22652 \u03c6\u03bf\u03c1\u03ad\u03c2 \u03bc\u03b5 \u226512 \u03bc\u03ae\u03bd\u03b5\u03c2 \u03b4\u03b9\u03b1\u03c6\u03bf\u03c1\u03ac.<\/li>\n<li><strong>MRD-guided \u03c3\u03c4\u03c1\u03b1\u03c4\u03b7\u03b3\u03b9\u03ba\u03ad\u03c2<\/strong>: \u03c5\u03c0\u03cc \u03b4\u03b9\u03b5\u03c1\u03b5\u03cd\u03bd\u03b7\u03c3\u03b7 \u03b3\u03b9\u03b1 \u03b1\u03c0\u03bf-\u03ba\u03bb\u03b9\u03bc\u03ac\u03ba\u03c9\u03c3\u03b7 \u03c3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7\u03c2\u00b7 \u03b5\u03ba\u03c4\u03cc\u03c2 \u03c1\u03bf\u03c5\u03c4\u03af\u03bd\u03b1\u03c2 \u03c3\u03b5 \u03c0\u03bf\u03bb\u03bb\u03bf\u03cd\u03c2.<\/li>\n<\/ul>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= SECTION 15 ========================= --><\/p>\n<h2 id=\"sec-15\" class=\"anchor\">15) \u03a0\u03c1\u03cc\u03b3\u03bd\u03c9\u03c3\u03b7 &amp; \u03a0\u03b1\u03c1\u03ac\u03b3\u03bf\u03bd\u03c4\u03b5\u03c2 \u039a\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5<\/h2>\n<div class=\"infobox neutral\">\n<h4>\u0393\u03b5\u03bd\u03b9\u03ba\u03ae \u03b5\u03b9\u03ba\u03cc\u03bd\u03b1<\/h4>\n<p>\u0397 \u03c0\u03c1\u03cc\u03b3\u03bd\u03c9\u03c3\u03b7 \u03ba\u03b1\u03b8\u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7 \u03b2\u03b9\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u03c4\u03bf\u03c5 \u03cc\u03b3\u03ba\u03bf\u03c5 (\u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03bf\u03b3\u03b5\u03bd\u03b5\u03c4\u03b9\u03ba\u03ae\/\u03bc\u03bf\u03c1\u03b9\u03b1\u03ba\u03ac), \u03c4\u03bf \u03c6\u03bf\u03c1\u03c4\u03af\u03bf \u03bd\u03cc\u03c3\u03bf\u03c5, \u03c4\u03b7\u03bd \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7\/ MRD \u03ba\u03b1\u03b9 \u03c4\u03b1 \u03c7\u03b1\u03c1\u03b1\u03ba\u03c4\u03b7\u03c1\u03b9\u03c3\u03c4\u03b9\u03ba\u03ac \u03b1\u03c3\u03b8\u03b5\u03bd\u03bf\u03cd\u03c2 (\u03b7\u03bb\u03b9\u03ba\u03af\u03b1, frailty, \u03c3\u03c5\u03bd\u03bd\u03bf\u03c3\u03b7\u03c1\u03cc\u03c4\u03b7\u03c4\u03b5\u03c2).<\/p>\n<\/div>\n<div class=\"table-scroll\">\n<table>\n<thead>\n<tr>\n<th>\u03a0\u03b1\u03c1\u03ac\u03b3\u03bf\u03bd\u03c4\u03b1\u03c2<\/th>\n<th>\u03a5\u03c8\u03b7\u03bb\u03bf\u03cd \u03ba\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\n<th>\u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u03c3\u03c5\u03bd\u03ad\u03c0\u03b5\u03b9\u03b1<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Cytogenetics\/FISH<\/td>\n<td>del(17p), t(4;14), t(14;16), amp\/gain 1q<\/td>\n<td>\u0395\u03bd\u03b9\u03c3\u03c7\u03c5\u03bc\u03ad\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\/\u03c3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7, \u03c3\u03c4\u03b5\u03bd\u03ae \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7<\/td>\n<\/tr>\n<tr>\n<td>\u03a3\u03c4\u03b1\u03b4\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7<\/td>\n<td>ISS\/R-ISS \u03c5\u03c8\u03b7\u03bb\u03cc\u03c4\u03b5\u03c1\u03b1 \u03c3\u03c4\u03ac\u03b4\u03b9\u03b1, R2-ISS<\/td>\n<td>\u03a0\u03c1\u03cc\u03b2\u03bb\u03b5\u03c8\u03b7 PFS\/OS, \u03bf\u03c1\u03af\u03b6\u03b5\u03b9 \u03ad\u03bd\u03c4\u03b1\u03c3\u03b7<\/td>\n<\/tr>\n<tr>\n<td>LDH<\/td>\n<td>\u0391\u03c5\u03be\u03b7\u03bc\u03ad\u03bd\u03b7<\/td>\n<td>\u0388\u03bd\u03b4\u03b5\u03b9\u03be\u03b7 \u03b5\u03c0\u03b9\u03b8\u03b5\u03c4\u03b9\u03ba\u03ae\u03c2 \u03b2\u03b9\u03bf\u03bb\u03bf\u03b3\u03af\u03b1\u03c2<\/td>\n<\/tr>\n<tr>\n<td>Extramedullary disease (EMD)<\/td>\n<td>\u039c\u03b1\u03bb\u03b1\u03ba\u03ce\u03bd \u03bc\u03bf\u03c1\u03af\u03c9\u03bd\/\u03c3\u03c0\u03bb\u03b1\u03c7\u03bd\u03b9\u03ba\u03cc<\/td>\n<td>\u03a0\u03b9\u03bf \u03b5\u03c0\u03b9\u03b8\u03b5\u03c4\u03b9\u03ba\u03ae \u03c4\u03b1\u03ba\u03c4\u03b9\u03ba\u03ae, \u03c3\u03c5\u03c7\u03bd\u03ac PI\/anti-CD38<\/td>\n<\/tr>\n<tr>\n<td>Circulating plasma cells<\/td>\n<td>cPC \u03c5\u03c8\u03b7\u03bb\u03ac \/ PCL \u03c7\u03b1\u03c1\u03b1\u03ba\u03c4\u03b7\u03c1\u03b9\u03c3\u03c4\u03b9\u03ba\u03ac<\/td>\n<td>\u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1, \u03c0\u03b9\u03b8\u03b1\u03bd\u03ae ASCT \u03bd\u03c9\u03c1\u03af\u03c2<\/td>\n<\/tr>\n<tr>\n<td>MRD<\/td>\n<td>\u0395\u03c0\u03b9\u03bc\u03bf\u03bd\u03ae MRD(+)<\/td>\n<td>\u03a7\u03b5\u03b9\u03c1\u03cc\u03c4\u03b5\u03c1\u03b7 \u03c0\u03c1\u03cc\u03b3\u03bd\u03c9\u03c3\u03b7\u00b7 \u03c3\u03ba\u03ad\u03c8\u03b7 \u03b3\u03b9\u03b1 \u03b5\u03bd\u03af\u03c3\u03c7\u03c5\u03c3\u03b7<\/td>\n<\/tr>\n<tr>\n<td>\u0391\u03c3\u03ae\u03ba.<\/td>\n<td>Frailty, \u03c3\u03c5\u03bd\u03bd\u03bf\u03c3\u03b7\u03c1\u03cc\u03c4\u03b7\u03c4\u03b5\u03c2<\/td>\n<td>\u03a0\u03b5\u03c1\u03b9\u03bf\u03c1\u03af\u03b6\u03b5\u03b9 \u03ad\u03bd\u03c4\u03b1\u03c3\u03b7, \u03b5\u03c0\u03b7\u03c1\u03b5\u03ac\u03b6\u03b5\u03b9 OS \u03b1\u03bd\u03b5\u03be\u03ac\u03c1\u03c4\u03b7\u03c4\u03b1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= SECTION 16 ========================= --><\/p>\n<h2 id=\"sec-16\" class=\"anchor\">16) \u0395\u03b9\u03b4\u03b9\u03ba\u03ad\u03c2 \u039a\u03b1\u03c4\u03b1\u03c3\u03c4\u03ac\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3>16.1 \u039d\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u0391\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 &amp; \u0391\u03b9\u03bc\u03bf\u03ba\u03ac\u03b8\u03b1\u03c1\u03c3\u03b7<\/h3>\n<ul>\n<li><strong>\u03a4\u03b1\u03c7\u03b5\u03af\u03b1 \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 FLC<\/strong> \u03bc\u03b5 <em>bortezomib-based<\/em> + \u03c5\u03c8\u03b7\u03bb\u03ae \u03b4\u03cc\u03c3\u03b7 \u03b4\u03b5\u03be\u03b1\u03bc\u03b5\u03b8\u03b1\u03b6\u03cc\u03bd\u03b7\u03c2.<\/li>\n<li>\u03a0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ad\u03c2 \u03b4\u03cc\u03c3\u03b5\u03c9\u03bd IMiDs (\u03b9\u03b4\u03af\u03c9\u03c2 len\/pom) \u03ba\u03b1\u03c4\u03ac eGFR.<\/li>\n<li>\u0391\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u03bd\u03b5\u03c6\u03c1\u03bf\u03c4\u03bf\u03be\u03b9\u03ba\u03ce\u03bd (\u039c\u03a3\u0391\u03a6, \u03c3\u03ba\u03b9\u03b1\u03b3\u03c1\u03b1\u03c6\u03b9\u03ba\u03ac) \u03ba\u03b1\u03b9 \u03c0\u03c1\u03bf\u03c3\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u03b5\u03bd\u03c5\u03b4\u03ac\u03c4\u03c9\u03c3\u03b7.<\/li>\n<li>\u03a3\u03b5 \u03b1\u03b9\u03bc\u03bf\u03ba\u03ac\u03b8\u03b1\u03c1\u03c3\u03b7: \u03c3\u03c5\u03b3\u03c7\u03c1\u03bf\u03bd\u03b9\u03c3\u03bc\u03cc\u03c2 \u03c7\u03bf\u03c1\u03b7\u03b3\u03ae\u03c3\u03b5\u03c9\u03bd \u03ba\u03b1\u03b9 \u03ad\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2 \u03b5\u03c0\u03b9\u03c0\u03ad\u03b4\u03c9\u03bd \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd\/\u03b7\u03bb\u03b5\u03ba\u03c4\u03c1\u03bf\u03bb\u03c5\u03c4\u03ce\u03bd.<\/li>\n<\/ul>\n<h3>16.2 \u0395\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7 (\u03c3\u03c0\u03ac\u03bd\u03b9\u03b1)<\/h3>\n<ul>\n<li><strong>IMiDs<\/strong> \u03b1\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03ba\u03bd\u03c5\u03bd\u03c4\u03b1\u03b9 (\u03c4\u03b5\u03c1\u03b1\u03c4\u03bf\u03b3\u03cc\u03bd\u03b1)\u00b7 \u03b1\u03c0\u03b1\u03b9\u03c4\u03b5\u03af\u03c4\u03b1\u03b9 <em>\u03c5\u03c8\u03b7\u03bb\u03bf\u03cd \u03b5\u03c0\u03b9\u03c0\u03ad\u03b4\u03bf\u03c5<\/em> \u03c3\u03c5\u03bc\u03b2\u03bf\u03c5\u03bb\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae.<\/li>\n<li>\u03a0\u03c1\u03bf\u03c3\u03b5\u03ba\u03c4\u03b9\u03ba\u03ae \u03c7\u03c1\u03ae\u03c3\u03b7 \u03c3\u03c4\u03b5\u03c1\u03bf\u03b5\u03b9\u03b4\u03ce\u03bd\/PI \u03bc\u03cc\u03bd\u03bf \u03cc\u03c4\u03b1\u03bd \u03b1\u03c0\u03bf\u03bb\u03cd\u03c4\u03c9\u03c2 \u03b1\u03c0\u03b1\u03c1\u03b1\u03af\u03c4\u03b7\u03c4\u03bf, \u03c3\u03b5 \u03b5\u03be\u03b5\u03b9\u03b4\u03b9\u03ba\u03b5\u03c5\u03bc\u03ad\u03bd\u03b1 \u03ba\u03ad\u03bd\u03c4\u03c1\u03b1.<\/li>\n<li>\u0394\u03b9\u03b5\u03c0\u03b9\u03c3\u03c4\u03b7\u03bc\u03bf\u03bd\u03b9\u03ba\u03ae \u03bf\u03bc\u03ac\u03b4\u03b1: \u03b1\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03cc\u03b3\u03bf\u03c2, \u03bc\u03b1\u03b9\u03b5\u03c5\u03c4\u03ae\u03c1\u03b1\u03c2-\u03b5\u03bc\u03b2\u03c1\u03c5\u03bf\u03bb\u03cc\u03b3\u03bf\u03c2, \u03bd\u03b5\u03c6\u03c1\u03bf\u03bb\u03cc\u03b3\u03bf\u03c2, \u03bb\u03bf\u03b9\u03bc\u03c9\u03be\u03b9\u03bf\u03bb\u03cc\u03b3\u03bf\u03c2.<\/li>\n<\/ul>\n<h3>16.3 AL \u0391\u03bc\u03c5\u03bb\u03bf\u03b5\u03af\u03b4\u03c9\u03c3\u03b7 (\u03c3\u03c5\u03bd\u03cd\u03c0\u03b1\u03c1\u03be\u03b7\/\u03c5\u03c0\u03bf\u03c8\u03af\u03b1)<\/h3>\n<ul>\n<li>\u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ac \u00abflags\u00bb: \u03bd\u03b5\u03c6\u03c1\u03c9\u03c3\u03b9\u03ba\u03cc, \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae (HS-troponin\/NT-proBNP \u2191), \u03c0\u03b5\u03c1\u03b9\u03c6\u03b5\u03c1\u03b9\u03ba\u03ae \u03bd\u03b5\u03c5\u03c1\u03bf\u03c0\u03ac\u03b8\u03b5\u03b9\u03b1\/\u03bf\u03c1\u03b8\u03bf\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03c0\u03cc\u03c4\u03b1\u03c3\u03b7.<\/li>\n<li>\u0394\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7: \u03b2\u03b9\u03bf\u03c8\u03af\u03b1 \u03bc\u03b5 \u03ba\u03cc\u03ba\u03ba\u03b9\u03bd\u03bf \u03c4\u03bf\u03c5 \u039a\u03bf\u03bd\u03b3\u03ba\u03cc (\u03c3\u03cd\u03bd\u03b4\u03b5\u03c3\u03b7) + \u03c4\u03c5\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7.<\/li>\n<li>\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u03ba\u03b1\u03c4\u03b5\u03cd\u03b8\u03c5\u03bd\u03c3\u03b7: <em>bortezomib-based<\/em>, <em>daratumumab<\/em> \u03ba\u03b1\u03c4\u03ac \u03ad\u03bd\u03b4\u03b5\u03b9\u03be\u03b7\u00b7 \u03c0\u03c1\u03bf\u03c3\u03bf\u03c7\u03ae \u03c3\u03c4\u03b7\u03bd \u03ba\u03b1\u03c1\u03b4-\u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03c4\u03bf\u03be\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1.<\/li>\n<\/ul>\n<h3>16.4 Solitary Plasmacytoma<\/h3>\n<ul>\n<li>\u039c\u03bf\u03bd\u03b1\u03b4\u03b9\u03ba\u03ae \u03b2\u03bb\u03ac\u03b2\u03b7 (\u03bf\u03c3\u03c4\u03b9\u03ba\u03ae\/\u03b5\u03be\u03c9\u03bf\u03c3\u03c4\u03b9\u03ba\u03ae) \u03c7\u03c9\u03c1\u03af\u03c2 \u03c3\u03c5\u03c3\u03c4\u03b7\u03bc\u03b1\u03c4\u03b9\u03ba\u03cc \u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1: <strong>\u03b1\u03ba\u03c4\u03b9\u03bd\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1<\/strong> \u00b1 \u03c3\u03cd\u03bd\u03c4\u03bf\u03bc\u03b7 \u03c3\u03c5\u03c3\u03c4\u03b7\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03b1\u03b3\u03c9\u03b3\u03ae \u03ba\u03b1\u03c4\u03ac \u03c0\u03b5\u03c1\u03af\u03c0\u03c4\u03c9\u03c3\u03b7.<\/li>\n<li>\u03a3\u03c4\u03b5\u03bd\u03ae \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7 \u03b3\u03b9\u03b1 \u03b5\u03be\u03ad\u03bb\u03b9\u03be\u03b7 \u03c3\u03b5 MM.<\/li>\n<\/ul>\n<h3>16.5 HBV\/HSV\/VZV &amp; \u039b\u03b1\u03bd\u03b8\u03ac\u03bd\u03bf\u03c5\u03c3\u03b5\u03c2 \u039b\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2<\/h3>\n<ul>\n<li>Screening HBV \u03c3\u03b5 \u03cc\u03bb\u03bf\u03c5\u03c2\u00b7 <strong>\u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7<\/strong> \u03c3\u03b5 HBsAg(+)\/antiHBc(+) \u03ba\u03b1\u03c4\u03ac \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 anti-CD38\/\u03b9\u03c3\u03c7\u03c5\u03c1\u03ae \u03b1\u03bd\u03bf\u03c3\u03bf\u03ba\u03b1\u03c4\u03b1\u03c3\u03c4\u03bf\u03bb\u03ae.<\/li>\n<li>\u0391\u03bd\u03c4\u03b9-\u03b9\u03b9\u03ba\u03ae \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7 VZV\/HSV \u03bc\u03b5 PI\/anti-CD38\/BsAbs\/CAR-T (\u03b2\u03bb. \u00a712.3).<\/li>\n<\/ul>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= SECTION 17 ========================= --><\/p>\n<h2 id=\"sec-17\" class=\"anchor\">17) \u0396\u03c9\u03ae \u03bc\u03b5 \u039c\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1: \u03a0\u03bf\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1 \u0396\u03c9\u03ae\u03c2, \u0394\u03b9\u03b1\u03c4\u03c1\u03bf\u03c6\u03ae, \u0386\u03c3\u03ba\u03b7\u03c3\u03b7, \u0395\u03c1\u03b3\u03b1\u03c3\u03af\u03b1\/\u03a4\u03b1\u03be\u03af\u03b4\u03b9\u03b1<\/h2>\n<h3>17.1 \u03a0\u03bf\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1 \u0396\u03c9\u03ae\u03c2 (QoL)<\/h3>\n<ul>\n<li>\u03a3\u03c4\u03bf\u03c7\u03b5\u03c5\u03bc\u03ad\u03bd\u03b7 \u03b4\u03b9\u03b1\u03c7\u03b5\u03af\u03c1\u03b9\u03c3\u03b7 \u03c0\u03cc\u03bd\u03bf\u03c5 (\u03b1\u03bd\u03b1\u03bb\u03b3\u03b7\u03c4\u03b9\u03ba\u03ae \u03ba\u03bb\u03af\u03bc\u03b1\u03ba\u03b1, \u03b5\u03c0\u03b5\u03bc\u03b2\u03b1\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c4\u03b5\u03c7\u03bd\u03b9\u03ba\u03ad\u03c2 \u03cc\u03c0\u03bf\u03c5 \u03c7\u03c1\u03b5\u03b9\u03ac\u03b6\u03b5\u03c4\u03b1\u03b9).<\/li>\n<li>\u03a8\u03c5\u03c7\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03c3\u03c4\u03ae\u03c1\u03b9\u03be\u03b7: \u03ac\u03b3\u03c7\u03bf\u03c2\/\u03ba\u03b1\u03c4\u03ac\u03b8\u03bb\u03b9\u03c8\u03b7, \u03bf\u03bc\u03ac\u03b4\u03b5\u03c2 \u03c5\u03c0\u03bf\u03c3\u03c4\u03ae\u03c1\u03b9\u03be\u03b7\u03c2.<\/li>\n<li>\u038e\u03c0\u03bd\u03bf\u03c2\/\u03ba\u03cc\u03c0\u03c9\u03c3\u03b7: \u03c5\u03b3\u03b9\u03b5\u03b9\u03bd\u03ae \u03cd\u03c0\u03bd\u03bf\u03c5, \u03c3\u03c4\u03b1\u03b4\u03b9\u03b1\u03ba\u03ae \u03b1\u03cd\u03be\u03b7\u03c3\u03b7 \u03b4\u03c1\u03b1\u03c3\u03c4\u03b7\u03c1\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2.<\/li>\n<\/ul>\n<h3>17.2 \u0394\u03b9\u03b1\u03c4\u03c1\u03bf\u03c6\u03ae<\/h3>\n<ul>\n<li><strong>\u039c\u03b5\u03c3\u03bf\u03b3\u03b5\u03b9\u03b1\u03ba\u03ae<\/strong> \u03c0\u03c1\u03bf\u03c3\u03ad\u03b3\u03b3\u03b9\u03c3\u03b7: \u03c6\u03c1\u03bf\u03cd\u03c4\u03b1\/\u03bb\u03b1\u03c7\u03b1\u03bd\u03b9\u03ba\u03ac, \u03cc\u03c3\u03c0\u03c1\u03b9\u03b1, \u03bf\u03bb\u03b9\u03ba\u03ae\u03c2, \u03c8\u03ac\u03c1\u03b9\u03b1, \u03b5\u03bb\u03b1\u03b9\u03cc\u03bb\u03b1\u03b4\u03bf.<\/li>\n<li>\u0395\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2 (\u03b9\u03b4\u03af\u03c9\u03c2 \u03c3\u03b5 \u03c3\u03b1\u03c1\u03ba\u03bf\u03c0\u03b5\u03bd\u03af\u03b1) \u03bc\u03b5 \u03ba\u03b1\u03b8\u03bf\u03b4\u03ae\u03b3\u03b7\u03c3\u03b7 \u03b4\u03b9\u03b1\u03b9\u03c4\u03bf\u03bb\u03cc\u03b3\u03bf\u03c5.<\/li>\n<li>\u0391\u03c3\u03c6\u03ac\u03bb\u03b5\u03b9\u03b1 \u03c4\u03c1\u03bf\u03c6\u03af\u03bc\u03c9\u03bd \u03c3\u03b5 \u03bf\u03c5\u03b4\u03b5\u03c4\u03b5\u03c1\u03bf\u03c0\u03b5\u03bd\u03af\u03b1 (\u03b1\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u03c9\u03bc\u03ce\u03bd\/\u03bc\u03b7 \u03c0\u03b1\u03c3\u03c4\u03b5\u03c1\u03b9\u03c9\u03bc\u03ad\u03bd\u03c9\u03bd).<\/li>\n<li>\u03a5\u03b3\u03c1\u03ac: \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03b1 \u03bc\u03b5 \u03b2\u03ac\u03c3\u03b7 \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1 \u03ba\u03b1\u03b9 \u03b1\u03c3\u03b2\u03ad\u03c3\u03c4\u03b9\u03bf.<\/li>\n<\/ul>\n<h3>17.3 \u0386\u03c3\u03ba\u03b7\u03c3\u03b7<\/h3>\n<ul>\n<li>\u03a0\u03c1\u03bf\u03b3\u03c1\u03ac\u03bc\u03bc\u03b1\u03c4\u03b1 <strong>\u03c7\u03b1\u03bc\u03b7\u03bb\u03ae\u03c2 \u03ad\u03c9\u03c2 \u03bc\u03ad\u03c4\u03c1\u03b9\u03b1\u03c2 \u03ad\u03bd\u03c4\u03b1\u03c3\u03b7\u03c2<\/strong> \u03bc\u03b5 \u03c6\u03c5\u03c3\u03b9\u03ba\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03ae (\u03b5\u03b9\u03b4\u03b9\u03ba\u03ac \u03b3\u03b9\u03b1 \u03c3\u03ba\u03b5\u03bb\u03b5\u03c4\u03cc).<\/li>\n<li>\u0391\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u03ad\u03bd\u03c4\u03bf\u03bd\u03c9\u03bd \u03c6\u03bf\u03c1\u03c4\u03af\u03c9\u03bd\/\u03ba\u03ac\u03bc\u03c8\u03b5\u03c9\u03bd \u03c3\u03b5 \u03c3\u03c0\u03bf\u03bd\u03b4\u03c5\u03bb\u03b9\u03ba\u03ad\u03c2 \u03b2\u03bb\u03ac\u03b2\u03b5\u03c2\u00b7 \u03c7\u03c1\u03ae\u03c3\u03b7 \u03bf\u03c1\u03b8\u03ce\u03c3\u03b5\u03c9\u03bd \u03cc\u03c0\u03bf\u03c5 \u03c7\u03c1\u03b5\u03b9\u03ac\u03b6\u03b5\u03c4\u03b1\u03b9.<\/li>\n<\/ul>\n<h3>17.4 \u0395\u03c1\u03b3\u03b1\u03c3\u03af\u03b1, \u03a4\u03b1\u03be\u03af\u03b4\u03b9\u03b1 &amp; \u0395\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03bf\u03af<\/h3>\n<ul>\n<li>\u0395\u03c5\u03ad\u03bb\u03b9\u03ba\u03c4\u03b7 \u03b5\u03c0\u03b9\u03c3\u03c4\u03c1\u03bf\u03c6\u03ae \u03c3\u03c4\u03b7\u03bd \u03b5\u03c1\u03b3\u03b1\u03c3\u03af\u03b1 \u03b1\u03bd\u03ac \u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b1\/\u03b1\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u03b5\u03b9\u03ba\u03cc\u03bd\u03b1.<\/li>\n<li>\u03a4\u03b1\u03be\u03af\u03b4\u03b9\u03b1: \u03c3\u03c7\u03ad\u03b4\u03b9\u03bf \u03b3\u03b9\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1\/\u03c8\u03cd\u03be\u03b7 (\u03c0.\u03c7. \u03b5\u03bd\u03ad\u03c3\u03b9\u03bc\u03b1), \u03ad\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2 \u03b1\u03c3\u03c6\u03b1\u03bb\u03b9\u03c3\u03c4\u03b9\u03ba\u03ae\u03c2 \u03ba\u03ac\u03bb\u03c5\u03c8\u03b7\u03c2, \u03b1\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u03c3\u03c5\u03bd\u03c9\u03c3\u03c4\u03b9\u03c3\u03bc\u03ce\u03bd \u03c3\u03b5 \u03b2\u03b1\u03c1\u03b9\u03ac \u03b1\u03bd\u03bf\u03c3\u03bf\u03ba\u03b1\u03c4\u03b1\u03c3\u03c4\u03bf\u03bb\u03ae.<\/li>\n<li>\u0395\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03bf\u03af (\u03b2\u03bb. \u00a712.3): \u03c0\u03c1\u03bf\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1\u03c4\u03b9\u03c3\u03bc\u03cc\u03c2 \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03ad\u03bd\u03c4\u03bf\u03bd\u03b5\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b5\u03c2 \u03cc\u03c0\u03bf\u03c5 \u03b5\u03c6\u03b9\u03ba\u03c4\u03cc.<\/li>\n<\/ul>\n<h3>17.5 \u03a3\u03c4\u03bf\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03a5\u03b3\u03b5\u03af\u03b1 &amp; MRONJ<\/h3>\n<ul>\n<li>\u039f\u03b4\u03bf\u03bd\u03c4\u03b9\u03b1\u03c4\u03c1\u03b9\u03ba\u03cc\u03c2 \u03ad\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2 \u03c0\u03c1\u03bf\/\u03ba\u03b1\u03c4\u03ac \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 \u03b4\u03b9\u03c6\u03c9\u03c3\u03c6\u03bf\u03bd\u03b9\u03ba\u03ac\/\u03bd\u03c4\u03b5\u03bd\u03bf\u03c3\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7.<\/li>\n<li>\u0395\u03bb\u03b1\u03c7\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03b5\u03be\u03b1\u03b3\u03c9\u03b3\u03ce\u03bd\/\u03c4\u03c1\u03b1\u03c5\u03bc\u03b1\u03c4\u03b9\u03ba\u03ce\u03bd \u03c0\u03c1\u03ac\u03be\u03b5\u03c9\u03bd \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b4\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2\u00b7 \u03b5\u03c0\u03b9\u03bc\u03b5\u03bb\u03ae\u03c2 \u03c3\u03c4\u03bf\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03b3\u03b9\u03b5\u03b9\u03bd\u03ae.<\/li>\n<\/ul>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= SECTION 18 ========================= --><\/p>\n<h2 id=\"sec-18\" class=\"anchor\">18) \u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2 (FAQ)<\/h2>\n<details>\n<summary><strong>\u03a0\u03cc\u03c4\u03b5 \u03be\u03b5\u03ba\u03b9\u03bd\u03ce \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1; \u03a4\u03b9 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03b1 SLiM-CRAB;<\/strong><\/summary>\n<div class=\"infobox neutral\">\n<p>\u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03be\u03b5\u03ba\u03b9\u03bd\u03ac \u03cc\u03c4\u03b1\u03bd \u03c5\u03c0\u03ac\u03c1\u03c7\u03b5\u03b9 <strong>\u03b5\u03bd\u03b5\u03c1\u03b3\u03cc \u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1<\/strong> \u03b2\u03ac\u03c3\u03b5\u03b9 IMWG: \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b1 SLiM (BMPC \u226560%, FLC ratio \u2265100, &gt;1 \u03b5\u03c3\u03c4\u03b9\u03b1\u03ba\u03ae MRI \u22655 mm) <em>\u03ae<\/em> \u03c4\u03b1 CRAB (\u03c5\u03c0\u03b5\u03c1\u03b1\u03c3\u03b2\u03b5\u03c3\u03c4\u03b9\u03b1\u03b9\u03bc\u03af\u03b1, \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b2\u03bb\u03ac\u03b2\u03b7, \u03b1\u03bd\u03b1\u03b9\u03bc\u03af\u03b1, \u03bf\u03c3\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b2\u03bb\u03ac\u03b2\u03b5\u03c2).<\/p>\n<\/div>\n<\/details>\n<details>\n<summary><strong>\u03a7\u03c1\u03b5\u03b9\u03ac\u03b6\u03bf\u03bc\u03b1\u03b9 \u03c0\u03ac\u03bd\u03c4\u03b1 \u03bc\u03b5\u03c4\u03b1\u03bc\u03cc\u03c3\u03c7\u03b5\u03c5\u03c3\u03b7;<\/strong><\/summary>\n<p>\u038c\u03c7\u03b9. \u0397 ASCT \u03c0\u03b1\u03c1\u03b1\u03bc\u03ad\u03bd\u03b5\u03b9 standard \u03b3\u03b9\u03b1 \u03ba\u03b1\u03c4\u03ac\u03bb\u03bb\u03b7\u03bb\u03bf\u03c5\u03c2, \u03b1\u03bb\u03bb\u03ac \u03c3\u03b5 \u03bc\u03b7 \u03c5\u03c0\u03bf\u03c8\u03ae\u03c6\u03b9\u03bf\u03c5\u03c2 \u03c5\u03c0\u03ac\u03c1\u03c7\u03bf\u03c5\u03bd <em>\u03b9\u03c3\u03c7\u03c5\u03c1\u03ac<\/em> \u03c3\u03c7\u03ae\u03bc\u03b1\u03c4\u03b1 (\u03c0.\u03c7. DRd, VRd-lite). \u0397 \u03b1\u03c0\u03cc\u03c6\u03b1\u03c3\u03b7 \u03b5\u03be\u03b1\u03c4\u03bf\u03bc\u03b9\u03ba\u03b5\u03cd\u03b5\u03c4\u03b1\u03b9.<\/p>\n<\/details>\n<details>\n<summary><strong>\u03a4\u03b9 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b7 \u00ab\u03c3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7\u00bb \u03ba\u03b1\u03b9 \u03c0\u03cc\u03c3\u03bf \u03b4\u03b9\u03b1\u03c1\u03ba\u03b5\u03af;<\/strong><\/summary>\n<p>\u03a3\u03c5\u03bd\u03ae\u03b8\u03c9\u03c2 <em>lenalidomide<\/em> \u03bc\u03b5\u03c4\u03ac ASCT \u03b3\u03b9\u03b1 \u03c0\u03b1\u03c1\u03ac\u03c4\u03b1\u03c3\u03b7 PFS\/OS. \u0394\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1: \u03c3\u03c5\u03bd\u03ae\u03b8\u03c9\u03c2 \u03bc\u03ad\u03c7\u03c1\u03b9 \u03c0\u03c1\u03cc\u03bf\u03b4\u03bf\u00b7 \u03c3\u03b5 standard-risk \u03ba\u03b1\u03b9 \u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03c4\u03b1\u03bc\u03ad\u03bd\u03b7 MRD(\u2013) \u03c3\u03c5\u03b6\u03b7\u03c4\u03b5\u03af\u03c4\u03b1\u03b9 <em>\u03b5\u03be\u03b1\u03c4\u03bf\u03bc\u03af\u03ba\u03b5\u03c5\u03c3\u03b7<\/em>.<\/p>\n<\/details>\n<details>\n<summary><strong>\u0391\u03bd \u03c5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03b9\u03ac\u03c3\u03c9, \u03c5\u03c0\u03ac\u03c1\u03c7\u03bf\u03c5\u03bd \u03b5\u03c0\u03b9\u03bb\u03bf\u03b3\u03ad\u03c2;<\/strong><\/summary>\n<p>\u039d\u03b1\u03b9: \u03c4\u03c1\u03b9\u03c0\u03bb\u03ad\u03c4\u03b5\u03c2\/\u03c4\u03b5\u03c4\u03c1\u03ac\u03c0\u03bb\u03b5\u03c4 \u03bc\u03b5 anti-CD38, carfilzomib, pomalidomide \u03ba.\u03ac. \u03a3\u03b5 \u03c0\u03c1\u03bf\u03c7\u03c9\u03c1\u03b7\u03bc\u03ad\u03bd\u03b5\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ad\u03c2 \u03c5\u03c0\u03ac\u03c1\u03c7\u03bf\u03c5\u03bd <strong>CAR-T<\/strong> \u03ba\u03b1\u03b9 <strong>\u03b4\u03b9\u03b5\u03b9\u03b4\u03b9\u03ba\u03ac \u03b1\u03bd\u03c4\u03b9\u03c3\u03ce\u03bc\u03b1\u03c4\u03b1<\/strong> (BCMA\/GPRC5D).<\/p>\n<\/details>\n<details>\n<summary><strong>\u03a4\u03b9 \u03b3\u03af\u03bd\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b5 \u03c4\u03b9\u03c2 \u03bb\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2;<\/strong><\/summary>\n<p>\u0395\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03bf\u03af, \u03b1\u03bd\u03c4\u03b9\u03ca\u03ba\u03ae\/PJP \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7 \u03ba\u03b1\u03c4\u03ac \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1, IVIG \u03c3\u03b5 \u03c5\u03c0\u03bf\u03c4\u03c1\u03bf\u03c0\u03b9\u03ac\u03b6\u03bf\u03c5\u03c3\u03b5\u03c2 \u03bb\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2. \u0395\u03c0\u03b9\u03ba\u03bf\u03b9\u03bd\u03ce\u03bd\u03b7\u03c3\u03b5 \u03ac\u03bc\u03b5\u03c3\u03b1 \u03b3\u03b9\u03b1 \u03c0\u03c5\u03c1\u03b5\u03c4\u03cc.<\/p>\n<\/details>\n<details>\n<summary><strong>\u03a0\u03ce\u03c2 \u03c0\u03c1\u03bf\u03c3\u03c4\u03b1\u03c4\u03b5\u03cd\u03c9 \u03c4\u03b1 \u03bf\u03c3\u03c4\u03ac \u03bc\u03bf\u03c5;<\/strong><\/summary>\n<p>\u0394\u03b9\u03c6\u03c9\u03c3\u03c6\u03bf\u03bd\u03b9\u03ba\u03ac \u03ae \u03bd\u03c4\u03b5\u03bd\u03bf\u03c3\u03bf\u03c5\u03bc\u03ac\u03bc\u03c0\u03b7, \u03b2\u03b9\u03c4\u03b1\u03bc\u03af\u03bd\u03b7 D\/\u03b1\u03c3\u03b2\u03ad\u03c3\u03c4\u03b9\u03bf \u03cc\u03c0\u03bf\u03c5 \u03b5\u03bd\u03b4\u03b5\u03af\u03ba\u03bd\u03c5\u03c4\u03b1\u03b9, \u03b1\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u03c0\u03c4\u03ce\u03c3\u03b5\u03c9\u03bd, \u03b5\u03be\u03b1\u03c4\u03bf\u03bc\u03b9\u03ba\u03b5\u03c5\u03bc\u03ad\u03bd\u03b7 \u03ac\u03c3\u03ba\u03b7\u03c3\u03b7. \u039f\u03b4\u03bf\u03bd\u03c4\u03b9\u03b1\u03c4\u03c1\u03b9\u03ba\u03cc\u03c2 \u03ad\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2 \u03c0\u03c1\u03b9\u03bd\/\u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b4\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1.<\/p>\n<\/details>\n<details>\n<summary><strong>\u039c\u03c0\u03bf\u03c1\u03ce \u03bd\u03b1 \u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ce \u03ae \u03bd\u03b1 \u03c4\u03b1\u03be\u03b9\u03b4\u03b5\u03cd\u03c9;<\/strong><\/summary>\n<p>\u03a3\u03c5\u03bd\u03ae\u03b8\u03c9\u03c2 \u03bd\u03b1\u03b9, \u03bc\u03b5 \u03c0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ad\u03c2. \u039f\u03c1\u03b3\u03ac\u03bd\u03c9\u03c3\u03b5 \u03c0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd, \u03b1\u03c0\u03cc\u03c6\u03c5\u03b3\u03b5 \u03c3\u03c5\u03bd\u03c9\u03c3\u03c4\u03b9\u03c3\u03bc\u03cc \u03c3\u03b5 \u03b2\u03b1\u03c1\u03b9\u03ac \u03b1\u03bd\u03bf\u03c3\u03bf\u03ba\u03b1\u03c4\u03b1\u03c3\u03c4\u03bf\u03bb\u03ae \u03ba\u03b1\u03b9 \u03c3\u03c5\u03bc\u03b2\u03bf\u03c5\u03bb\u03b5\u03cd\u03c3\u03bf\u03c5 \u03c4\u03bf\u03bd \u03b3\u03b9\u03b1\u03c4\u03c1\u03cc \u03c3\u03bf\u03c5 \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03bc\u03b5\u03b3\u03ac\u03bb\u03b5\u03c2 \u03bc\u03b5\u03c4\u03b1\u03ba\u03b9\u03bd\u03ae\u03c3\u03b5\u03b9\u03c2.<\/p>\n<\/details>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<p><!-- ========================= \u03a0\u039f\u039b\u039b\u0391\u03a0\u039b\u039f \u039c\u03a5\u0395\u039b\u03a9\u039c\u0391 \u2013 \u039f\u0394\u0397\u0393\u039f\u03a3 (\u039c\u0395\u03a1\u039f\u03a3 \u0394: Sections 19\u201320) Mobile-friendly HTML \u03b3\u03b9\u03b1 Classic Editor ========================= --><\/p>\n<p><!-- ========================= SECTION 19 ========================= --><\/p>\n<h2 id=\"sec-19\" class=\"anchor\">19) \u0392\u03b9\u03b2\u03bb\u03b9\u03bf\u03b3\u03c1\u03b1\u03c6\u03af\u03b1 &amp; \u0395\u03c0\u03b9\u03bb\u03b5\u03b3\u03bc\u03ad\u03bd\u03bf\u03b9 \u03a0\u03cc\u03c1\u03bf\u03b9 (\u03b4\u03b9\u03b5\u03b8\u03bd\u03b5\u03af\u03c2 &amp; \u03b5\u03bb\u03bb\u03b7\u03bd\u03b9\u03ba\u03bf\u03af)<\/h2>\n<p class=\"small\">\u03a3\u03b7\u03bc.: \u039f\u03b9 \u03c4\u03af\u03c4\u03bb\u03bf\u03b9 \u03bf\u03b4\u03b7\u03b3\u03bf\u03cd\u03bd \u03c3\u03b5 open-access \u03c0\u03b5\u03c1\u03af\u03bb\u03b7\u03c8\u03b7\/\u03ac\u03c1\u03b8\u03c1\u03bf \u03ae \u03c3\u03b5 \u03b5\u03c0\u03af\u03c3\u03b7\u03bc\u03b7 \u03c3\u03b5\u03bb\u03af\u03b4\u03b1 \u03bf\u03c1\u03b3\u03b1\u03bd\u03b9\u03c3\u03bc\u03bf\u03cd.<\/p>\n<h3>19.1 \u0394\u03b9\u03b1\u03b3\u03bd\u03c9\u03c3\u03c4\u03b9\u03ba\u03ac \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 &amp; \u03c3\u03c4\u03b1\u03b4\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7<\/h3>\n<ul>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25439696\/\" target=\"_blank\" rel=\"nofollow noopener\">IMWG updated criteria (SLiM\u2013CRAB): Lancet Oncology 2014<\/a> \u2013 \u039f \u03bf\u03c1\u03b9\u03c3\u03bc\u03cc\u03c2 \u03b5\u03bd\u03b5\u03c1\u03b3\u03bf\u03cd \u039c\u039c \u03bc\u03b5 \u03b2\u03b9\u03bf\u03b4\u03b5\u03af\u03ba\u03c4\u03b5\u03c2.<\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27249749\/\" target=\"_blank\" rel=\"nofollow noopener\">Rajkumar 2016 (\u03b1\u03bd\u03b1\u03c3\u03ba\u03cc\u03c0\u03b7\u03c3\u03b7 \u03ba\u03c1\u03b9\u03c4\u03b7\u03c1\u03af\u03c9\u03bd)<\/a> \u2013 \u03a3\u03cd\u03bd\u03c4\u03bf\u03bc\u03b7 \u03c0\u03b5\u03c1\u03af\u03bb\u03b7\u03c8\u03b7 \u03b1\u03bb\u03bb\u03b1\u03b3\u03ce\u03bd IMWG.<\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26240224\/\" target=\"_blank\" rel=\"nofollow noopener\">R-ISS (JCO 2015)<\/a> \u2013 \u0391\u03bd\u03b1\u03b8\u03b5\u03c9\u03c1\u03b7\u03bc\u03ad\u03bd\u03bf \u03c3\u03cd\u03c3\u03c4\u03b7\u03bc\u03b1 \u03c3\u03c4\u03b1\u03b4\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7\u03c2.<\/li>\n<li><a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.02614\" target=\"_blank\" rel=\"nofollow noopener\">R2-ISS (JCO 2022)<\/a> \u2013 \u0394\u03b5\u03cd\u03c4\u03b5\u03c1\u03b7 \u03b1\u03bd\u03b1\u03b8\u03b5\u03ce\u03c1\u03b7\u03c3\u03b7 \u03bc\u03b5 \u03ba\u03b1\u03bb\u03cd\u03c4\u03b5\u03c1\u03b7 \u03b4\u03b9\u03b1\u03c3\u03c4\u03c1\u03c9\u03bc\u03ac\u03c4\u03c9\u03c3\u03b7 \u03ba\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5.<\/li>\n<li><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8390819\/\" target=\"_blank\" rel=\"nofollow noopener\">Imaging \u03c3\u03b5 \u039c\u039c \u2013 \u03b5\u03bd\u03b7\u03bc\u03ad\u03c1\u03c9\u03c3\u03b7 \u03b2\u03ac\u03c3\u03b5\u03b9 IMWG<\/a> \u2013 LD-WBCT, PET-CT, WB-MRI.<\/li>\n<\/ul>\n<h3>19.2 \u03a0\u03c1\u03c9\u03c4\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 &amp; \u03ba\u03b1\u03c4\u03b5\u03c5\u03b8\u03c5\u03bd\u03c4\u03ae\u03c1\u03b9\u03b5\u03c2<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2312054\" target=\"_blank\" rel=\"nofollow noopener\">PERSEUS (NEJM 2024): D-VRd vs VRd (ASCT-eligible)<\/a> \u2013 \u03a5\u03c0\u03b5\u03c1\u03bf\u03c7\u03ae D-VRd.<\/li>\n<li><a href=\"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/5\/article-p132.xml?print=\" target=\"_blank\" rel=\"nofollow noopener\">NCCN Guidelines Insights 2025<\/a> \u2013 D-VRd \u03c9\u03c2 <em>preferred<\/em> \u03b3\u03b9\u03b1 NDMM \u03ba\u03b1\u03c4\u03ac\u03bb\u03bb\u03b7\u03bb\u03bf\u03c5\u03c2 \u03b3\u03b9\u03b1 ASCT.<\/li>\n<li><a href=\"https:\/\/ashpublications.org\/blood\/article\/136\/8\/936\/454474\/Daratumumab-lenalidomide-bortezomib-and\" target=\"_blank\" rel=\"nofollow noopener\">GRIFFIN (Blood 2020) \u2013 D-RVd vs RVd<\/a> \u2013 \u03a4\u03b5\u03ba\u03bc\u03b7\u03c1\u03af\u03c9\u03c3\u03b7 \u03c4\u03b5\u03c4\u03c1\u03b1\u03c0\u03bb\u03ad\u03c4\u03b1\u03c2.<\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29740809\/\" target=\"_blank\" rel=\"nofollow noopener\">RVD-lite (2018) \u2013 \u03bc\u03b5\u03c4\u03b1\u03bc\u03bf\u03c3\u03c7\u03b5\u03c5\u03c4\u03b9\u03ba\u03ac \u03b1\u03ba\u03b1\u03c4\u03ac\u03bb\u03bb\u03b7\u03bb\u03bf\u03b9\/\u03b7\u03bb\u03b9\u03ba\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf\u03b9<\/a> \u2013 \u0395\u03b2\u03b4\u03bf\u03bc\u03b1\u03b4\u03b9\u03b1\u03af\u03bf \u03c5\u03c0\u03bf\u03b4\u03cc\u03c1\u03b9\u03bf bortezomib, \u03bc\u03b5\u03b9\u03c9\u03bc\u03ad\u03bd\u03b5\u03c2 \u03b4\u03cc\u03c3\u03b5\u03b9\u03c2.<\/li>\n<li><a href=\"https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/myeloma-patient.pdf\" target=\"_blank\" rel=\"nofollow noopener\">NCCN \u03b3\u03b9\u03b1 \u0391\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 (PDF)<\/a> \u2013 \u03a6\u03b9\u03bb\u03b9\u03ba\u03cc \u03c6\u03c5\u03bb\u03bb\u03ac\u03b4\u03b9\u03bf \u03ba\u03b1\u03c4\u03b5\u03c5\u03b8\u03c5\u03bd\u03c4\u03b7\u03c1\u03af\u03c9\u03bd.<\/li>\n<\/ul>\n<h3>19.3 \u039d\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b2\u03bb\u03ac\u03b2\u03b7 \u03c3\u03c4\u03bf \u03bc\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1<\/h3>\n<ul>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37414019\/\" target=\"_blank\" rel=\"nofollow noopener\">IMWG: Renal impairment (Leukemia 2023)<\/a> \u2013 \u0391\u03bb\u03b3\u03cc\u03c1\u03b9\u03b8\u03bc\u03bf\u03c2 &amp; \u03bf\u03c1\u03b9\u03c3\u03bc\u03bf\u03af \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae\u03c2 \u03b1\u03bd\u03c4\u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7\u03c2.<\/li>\n<li><a href=\"https:\/\/www.myeloma.org\/resource-library\/imwg-recommendations-managing-multiple-myeloma-related-renal-impairment\" target=\"_blank\" rel=\"nofollow noopener\">IMF summary \u03c4\u03c9\u03bd \u03c3\u03c5\u03c3\u03c4\u03ac\u03c3\u03b5\u03c9\u03bd IMWG<\/a>.<\/li>\n<\/ul>\n<h3>19.4 \u039f\u03c3\u03c4\u03b9\u03ba\u03ae \u03bd\u03cc\u03c3\u03bf\u03c2 &amp; \u03c5\u03c0\u03b5\u03c1\u03b1\u03c3\u03b2\u03b5\u03c3\u03c4\u03b9\u03b1\u03b9\u03bc\u03af\u03b1<\/h3>\n<ul>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29429912\/\" target=\"_blank\" rel=\"nofollow noopener\">Denosumab vs Zoledronic Acid (Lancet 2018)<\/a> \u2013 \u039c\u03b7 \u03ba\u03b1\u03c4\u03c9\u03c4\u03b5\u03c1\u03cc\u03c4\u03b7\u03c4\u03b1 \u03b3\u03b9\u03b1 SREs.<\/li>\n<li><a href=\"https:\/\/multiplemyelomahub.com\/medical-information\/imwg-clinical-practice-guidelines-for-the-treatment-of-multiple-myeloma-related-bone-disease\" target=\"_blank\" rel=\"nofollow noopener\">IMWG Bone disease (2021) \u2013 \u03c3\u03cd\u03bd\u03bf\u03c8\u03b7<\/a>.<\/li>\n<li><a href=\"https:\/\/www.endocrine.org\/clinical-practice-guidelines\/hypercalcemia\" target=\"_blank\" rel=\"nofollow noopener\">Endocrine Society 2022 \u2013 \u03a5\u03c0\u03b5\u03c1\u03b1\u03c3\u03b2\u03b5\u03c3\u03c4\u03b9\u03b1\u03b9\u03bc\u03af\u03b1 \u03ba\u03b1\u03ba\u03bf\u03ae\u03b8\u03b5\u03b9\u03b1\u03c2<\/a> (J Clin Endocrinol Metab 2023).<\/li>\n<\/ul>\n<h3>19.5 \u039b\u03bf\u03b9\u03bc\u03ce\u03be\u03b5\u03b9\u03c2, \u03c0\u03c1\u03bf\u03c6\u03c5\u03bb\u03ac\u03be\u03b5\u03b9\u03c2 &amp; \u03b5\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03bf\u03af<\/h3>\n<ul>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35114152\/\" target=\"_blank\" rel=\"nofollow noopener\">IMWG Infection Prevention (Lancet Haematol 2022)<\/a> \u2013 \u0395\u03bc\u03b2\u03bf\u03bb\u03b9\u03b1\u03c3\u03bc\u03bf\u03af, \u03b1\u03bd\u03c4\u03b9-\u03b9\u03b9\u03ba\u03ae\/PJP \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7, IVIG \u03ba\u03b1\u03c4\u03ac \u03ad\u03bd\u03b4\u03b5\u03b9\u03be\u03b7.<\/li>\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41408-023-00879-7\" target=\"_blank\" rel=\"nofollow noopener\">Raje et\u00a0al., 2023 \u2013 Monitoring\/prophylaxis\/treatment of infections<\/a>.<\/li>\n<li><a href=\"https:\/\/emedicine.medscape.com\/article\/204369-guidelines\" target=\"_blank\" rel=\"nofollow noopener\">VTE \u03c0\u03c1\u03bf\u03c6\u03cd\u03bb\u03b1\u03be\u03b7 \u03bc\u03b5 IMiDs \u2013 \u03c3\u03cd\u03bd\u03bf\u03c8\u03b7 NCCN\/ASCO\/IMWG<\/a>.<\/li>\n<\/ul>\n<h3>19.6 \u039d\u03b5\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b5\u03c2 (CAR-T &amp; \u03b4\u03b9\u03b5\u03b9\u03b4\u03b9\u03ba\u03ac)<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2303379\" target=\"_blank\" rel=\"nofollow noopener\">Cilta-cel vs standard (NEJM 2023)<\/a> \u2013 PFS \u03cc\u03c6\u03b5\u03bb\u03bf\u03c2 \u03c3\u03b5 len-refractory RRMM.<\/li>\n<li><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2024850\" target=\"_blank\" rel=\"nofollow noopener\">Ide-cel (NEJM 2021\/2023)<\/a> \u2013 \u0391\u03c0\u03bf\u03b4\u03bf\u03c4\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1 \u03c3\u03b5 \u03b2\u03b1\u03c1\u03b9\u03ac \u03c0\u03c1\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03bc\u03ad\u03bd\u03bf\u03c5\u03c2.<\/li>\n<li><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2203478\" target=\"_blank\" rel=\"nofollow noopener\">Teclistamab (NEJM 2022)<\/a> \u2013 \u03a5\u03c8\u03b7\u03bb\u03ac \u03c0\u03bf\u03c3\u03bf\u03c3\u03c4\u03ac \u03b2\u03b1\u03b8\u03b9\u03ce\u03bd \u03b1\u03c0\u03bf\u03ba\u03c1\u03af\u03c3\u03b5\u03c9\u03bd.<\/li>\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41591-023-02528-9\" target=\"_blank\" rel=\"nofollow noopener\">Elranatamab (Nat Med 2023, MagnetisMM-3)<\/a>.<\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36507686\/\" target=\"_blank\" rel=\"nofollow noopener\">Talquetamab (NEJM 2022, MonumenTAL-1)<\/a>.<\/li>\n<li><a href=\"https:\/\/multiplemyelomahub.com\/medical-information\/emn-recommendations-prevention-and-management-of-car-t-and-bispecific-antibody-related-adverse-events-in-mm\" target=\"_blank\" rel=\"nofollow noopener\">EMN 2023 \u2013 \u03b4\u03b9\u03b1\u03c7\u03b5\u03af\u03c1\u03b9\u03c3\u03b7 AEs CAR-T\/bsAbs<\/a>.<\/li>\n<\/ul>\n<h3>19.7 Smoldering MM (SMM) \u2013 \u03bc\u03bf\u03bd\u03c4\u03ad\u03bb\u03b1 \u03ba\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5<\/h3>\n<ul>\n<li><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7567803\/\" target=\"_blank\" rel=\"nofollow noopener\">IMWG 2\/20\/20 risk model (2020)<\/a> \u2013 \u22652 \u03c0\u03b1\u03c1\u03ac\u03b3\u03bf\u03bd\u03c4\u03b5\u03c2 \u2192 ~50% \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2 2-\u03b5\u03c4\u03af\u03b1\u03c2.<\/li>\n<li><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9821526\/\" target=\"_blank\" rel=\"nofollow noopener\">The consultant\u2019s guide to SMM (2023)<\/a> \u2013 \u03c0\u03c1\u03b1\u03ba\u03c4\u03b9\u03ba\u03ae \u03b5\u03c6\u03b1\u03c1\u03bc\u03bf\u03b3\u03ae \u03bc\u03bf\u03bd\u03c4\u03ad\u03bb\u03c9\u03bd.<\/li>\n<\/ul>\n<h3>19.8 \u0395\u03bb\u03bb\u03b7\u03bd\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b7\u03b3\u03ad\u03c2\/\u03c5\u03bb\u03b9\u03ba\u03cc<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.hesmo.gr\/images\/EL-Multiple-Myeloma-Guide-for-Patients-Greek.pdf\" target=\"_blank\" rel=\"nofollow noopener\">ESMO Patient Guide (\u03b5\u03bb\u03bb\u03b7\u03bd\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03ac\u03c6\u03c1\u03b1\u03c3\u03b7, \u0395\u039f\u03a0\u0395)<\/a>.<\/li>\n<li><a href=\"https:\/\/eae.gr\/active-clinical-studies\/pollaplo-myeloma\/\" target=\"_blank\" rel=\"nofollow noopener\">\u0395\u03bb\u03bb\u03b7\u03bd\u03b9\u03ba\u03ae \u0391\u03b9\u03bc\u03b1\u03c4\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ae \u0395\u03c4\u03b1\u03b9\u03c1\u03b5\u03af\u03b1 \u2013 \u03c3\u03b5\u03bb\u03af\u03b4\u03b1 \u03bc\u03c5\u03b5\u03bb\u03ce\u03bc\u03b1\u03c4\u03bf\u03c2<\/a>.<\/li>\n<\/ul>\n<p class=\"small\"><a href=\"#toc\">\u2b06 \u03a0\u03af\u03c3\u03c9 \u03c3\u03c4\u03bf\u03bd TOC<\/a><\/p>\n<h2 data-start=\"2263\" data-end=\"2436\" data-rm-block-id=\"block-190\"><a href=\"https:\/\/mikrobiologikolamia.gr\/staging\/katalogos-eksetaseon\/\"><strong>\u03a0\u0391\u03a4\u0397\u03a3\u03a4\u0395 \u0395\u0394\u03a9 \u0393\u0399\u0391 \u03a4\u039f\u039d \u03a0\u039b\u0397\u03a1\u0397 \u039a\u0391\u03a4\u0391\u039b\u039f\u0393\u039f \u0395\u039e\u0395\u03a4\u0391\u03a3\u0395\u03a9\u039d \u039c\u0391\u03a3 \u039a\u0391\u0399 \u0396\u0397\u03a4\u0397\u03a3\u03a4\u0395 \u039c\u0391\u03a3 \u0391\u03a5\u03a4\u039f \u03a0\u039f\u03a5 \u03a3\u0391\u03a3 \u0395\u039d\u0394\u0399\u0391\u03a6\u0395\u03a1\u0395\u0399 !!<\/strong><\/a><\/h2>\n<h2 data-rm-block-id=\"block-191\"><a href=\"https:\/\/mikrobiologikolamia.gr\/staging\/katalogos-eksetaseon\/\">https:\/\/mikrobiologikolamia.gr\/staging\/katalogos-eksetaseon\/<\/a><\/h2>\n","protected":false},"excerpt":{"rendered":"<p>\ud83e\udded \u03a0\u03af\u03bd\u03b1\u03ba\u03b1\u03c2 \u03a0\u03b5\u03c1\u03b9\u03b5\u03c7\u03bf\u03bc\u03ad\u03bd\u03c9\u03bd (TOC) \ud83d\udcd1 \u03a0\u03b5\u03c1\u03b9\u03b5\u03c7\u03cc\u03bc\u03b5\u03bd\u03b1 1. \u03a4\u03b9 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03bf \u03a0\u03bf\u03bb\u03bb\u03b1\u03c0\u03bb\u03cc \u039c\u03c5\u03ad\u03bb\u03c9\u03bc\u03b1; \u039f\u03c1\u03b9\u03c3\u03bc\u03cc\u03c2 \u2013 \u0395\u03c0\u03b9\u03b4\u03b7\u03bc\u03b9\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u2013 \u03a6\u03c5\u03c3\u03b9\u03ba\u03ae \u03b9\u03c3\u03c4\u03bf\u03c1\u03af\u03b1 2. \u03a0\u03bb\u03b1\u03c3\u03bc\u03b1\u03c4\u03bf\u03ba\u03c5\u03c4\u03c4\u03b1\u03c1\u03b9\u03ba\u03ac \u03bd\u03bf\u03c3\u03ae\u03bc\u03b1\u03c4\u03b1: MGUS vs SMM vs MM 3. \u039a\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 \u0394\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2 (IMWG): SLiM\u2013CRAB 4. \u0394\u03b9\u03b1\u03b3\u03bd\u03c9\u03c3\u03c4\u03b9\u03ba\u03cc\u03c2 \u0388\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2: \u0395\u03c1\u03b3\u03b1\u03c3\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ac, \u0391\u03c0\u03b5\u03b9\u03ba\u03cc\u03bd\u03b9\u03c3\u03b7, MRD 5. \u03a3\u03c4\u03b1\u03b4\u03b9\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 &amp; \u039a\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2: ISS, R-ISS, R2-ISS 6. \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u0395\u03b9\u03ba\u03cc\u03bd\u03b1 &amp; \u0395\u03c0\u03b9\u03c0\u03bb\u03bf\u03ba\u03ad\u03c2 7. \u0398\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03a0\u03c1\u03ce\u03c4\u03b7\u03c2 \u0393\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2 (NDMM) 8. [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":4828,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2539],"tags":[1421,1418,1420,1428,1429,1415,1416,1414,1419,1417,1422,1427,1426,1425,1413,1423,504,1424],"class_list":["post-4823","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-odigoi-asthenon","tag-car-t","tag-daratumumab","tag-drd","tag-frailty","tag-mrd","tag-r-iss","tag-r2-iss","tag-slim-crab","tag-vrd","tag-avtologi-metamoschefsi","tag-dieidika-antisomata","tag-loimoxeis-sto-myeloma","tag-nefriki-vlavi","tag-ostiki-nosos","tag-pollaplo-myeloma","tag-syntirisi-therapeias","tag-yperasvestiaimia","tag-ypotropi-myelomatos"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/posts\/4823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/comments?post=4823"}],"version-history":[{"count":5,"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/posts\/4823\/revisions"}],"predecessor-version":[{"id":4830,"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/posts\/4823\/revisions\/4830"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/media\/4828"}],"wp:attachment":[{"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/media?parent=4823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/categories?post=4823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mikrobiologikolamia.gr\/staging\/wp-json\/wp\/v2\/tags?post=4823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}